Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae

Metabolic Syndrome: Underlying Mechanisms and Drug Therapies

Volumn , Issue , 2011, Pages 73-131

  Declercq, Vanessa ^a,b   Stringer, Danielle ^a,b   Hunt, Ryan ^a,b   Taylor, Carla G ^a,b   Zahradka, Peter ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

Author keywords

Adipokine production by adipose tissue novel target, treating metabolic syndrome and its sequelae; AMPK activation AMPK role, in regulating glucose and lipid metabolism; Relationship between MetS and cardiovascular disease risk

Indexed keywords

EID: 84872387730     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470910016.ch4     Document Type: Chapter

References (481)

1. POTENZA, M.V., and J.I. MECHANICK. 2009. The metabolic syndrome: definition, global impact, and pathophysiology. Nutr Clin Pract 24:560-577.
2. RECTOR, R.S., J.P. THYFAULT, Y. WEI, and J.A. IBDAH. 2008. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 14:185-192.
3. MAGLIANO, D.J., J.E. SHAW, and P.Z. ZIMMET. 2006. How to best define the metabolic syndrome. Ann Med 38:34-41.
4. FORD, E.S., W.H. GILES, and A.H. MOKDAD. 2004. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 27:2444-2449.
5. LIU, J., A.J.HANLEY, T.K.YOUNG, S.B.HARRIS, and B. ZINMAN. 2006. Characteristics and prevalence of the metabolic syndrome among three ethnic groups in Canada. Int J Obes (Lond) 30:669-676.
6. TJEPKEMA, M. 2005. Insomnia. Health Rep 17:9-25.
7. MEIGS, J.B. 2002. Epidemiology of the metabolic syndrome. 2002. Am J Manag Care 8:S283-S292.
8. ZHANG, Y., R. PROENCA, M. MAFFEI, M. BARONE, L. LEOPOLD, and J.M. FRIEDMAN. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432.
9. BAYS, H.E., J.M. GONZALEZ-CAMPOY, G.A. BRAY, A.E. KITABCHI, D.A. BERGMAN, A.B. SCHORR, H.W. RODBARD, and R.R. HENRY. 2008. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 6:343-368.
10. BAYS, H.E. 2009. "Sick fat," metabolic disease, and atherosclerosis. Am J Med 122:S26-S37.
11. BLUHER,M. 2009. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 117:241-250.
12. HAJER, G.R., T.W. VAN HAEFTEN, and F.L. VISSEREN. 2008. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 29:2959-2971.
13. SETHI, J.K. 2004. A burst of energy in metabolic disease research. Genome Biol 5:327.
14. AHIMA, R.S., and J.S. FLIER. 2000. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11:327-332.
15. AHIMA, R.S. 2006. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 14 (Suppl 5): 242S-249S.
16. KIESS, W., S. PETZOLD, M. TOPFER, A.GARTEN, S. BLUHER, T.KAPELLEN, A. KORNER, and J. KRATZSCH. 2008. Adipocytes and adipose tissue. Best Pract Res Clin Endocrinol Metab 22:135-153
17. FAUST, I.M., P.R. JOHNSON, J.S. STERN, and J.HIRSCH. 1978. Diet-induced adipocyte number increase in adult rats: a new model of obesity. Am J Physiol 235:E279-E286.
18. HIRSCH, J., and B. BATCHELOR. 1976. Adipose tissue cellularity in human obesity. Clin Endocrinol Metab 5:299-311.
19. BRUUN, J.M., A.S. LIHN, S.B. PEDERSEN, and B. RICHELSEN. 2005. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 90:2282-2289.
20. WEISBERG, S.P., D. MCCANN, M. DESAI, M. ROSENBAUM, R.L. LEIBEL, and A.W. FERRANTE, JR. 2003. OBESITY IS ASSOCIATED WITH MACROPHAGE ACCUMULATION IN ADIPOSE TISSUE. J CLIN INVEST 112:1796-1808.
21. CANCELLO, R., and K. CLEMENT. 2006. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG 113:1141-1147.
22. BOULOUMIE, A., C.A. CURAT, C. SENGENES, K. LOLMEDE, A. MIRANVILLE, and R. BUSSE. 2005. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 8:347-354.
23. KHAN, T., E.S. MUISE, P. IYENGAR, Z.V. WANG, M. CHANDALIA, N. ABATE, B.B. ZHANG, P. BONALDO, S. CHUA, and P.E. SCHERER. 2009. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 29:1575-1591.
24. XU, H., G.T. BARNES, Q. YANG, G. TAN, D. YANG, C.J. CHOU, J. SOLE, A. NICHOLS, J.S. ROSS, L. A. TARTAGLIA, and H. CHEN. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830.
25. MATSUZAWA,Y. 2005. White adipose tissue and cardiovascular disease. Best Pract Res Clin Endocrinol Metab 19:637-647.
26. LOPPNOW, H., K. WERDAN, and M. BUERKE. 2008. Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms. Innate Immun 14:63-87.
27. FRUHBECK, G. 2004. The adipose tissue as a source of vasoactive factors. Curr Med Chem Cardiovasc Hematol Agents 2:197-208.
28. LAFONTAN, M., and M. BERLAN. 2003. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci 24:276-283.
29. PHILLIPS, L.K., and J.B. PRINS. 2008. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 10:156-164.
30. DESPRES, J.P., B.J. ARSENAULT, M. COTE, A. CARTIER, and I. LEMIEUX. 2008. Abdominal obesity: the cholesterol of the 21st century? Can J Cardiol 24 (Suppl D): 7D-12D.
31. DESPRES, J.P., A. CARTIER, M. COTE, and B.J. ARSENAULT. 2008. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med 40:514-523.
32. BERGMAN, R.N. 2000. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 43:946-952.
33. RODRIGUEZ, A., V. CATALAN, J. GOMEZ-AMBROSI, and G. FRUHBECK. 2007. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des 13:2169-2175.
34. WANG, H., and R.H. ECKEL. 2009. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 297:E271-E288.
35. DELARUE, J., and C.MAGNAN. 2007. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 10:142-148.
36. FAIN, J.N., A.K.MADAN, M.L. HILER, P. CHEEMA, and S.W. BAHOUTH. 2004. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145:2273-2282.
37. FRIED, S.K., D.A. BUNKIN, and A.S. GREENBERG. 1998. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847-850.
38. DUSSERRE, E., P.MOULIN, and H.VIDAL. 2000. Differences inmRNAexpression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 1500:88-96.
39. ATZMON, G., X.M.YANG, R.MUZUMDAR, X.H.MA, I.GABRIELY, and N.BARZILAI. 2002. Differential gene expression between visceral and subcutaneous fat depots. Horm Metab Res 34:622-628.
40. EINSTEIN, F.H., G.ATZMON, X.M.YANG, X.H.MA,M.RINCON, E.RUDIN,R.MUZUMDAR, and N.BARZILAI. 2005. Differential responses of visceral and subcutaneous fat depots to nutrients. Diabetes 54:672-678.
41. FRIEDMAN, J.M., and J.L.HALAAS. 1998. Leptin and the regulation of body weight in mammals. Nature 395:763-770.
42. BELTOWSKI, J., G. WOJCICKA, and A. JAMROZ. 2003. Stimulatory effect of leptin on nitric oxide production is impaired in dietary-induced obesity. Obes Res 11:1571-1580.
43. RAHMOUNI, K., D.A. MORGAN, G.M. MORGAN, A.L. MARK, and W.G. HAYNES. 2005. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 54:2012-2018.
44. CORREIA, M.L., and K. RAHMOUNI. 2006. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab 8:603-610.
45. ANTUNA-PUENTE, B., B. FEVE, S. FELLAHI, and J.P. BASTARD. 2008. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 34:2-11.
46. MONTAGUE, C.T., J.B. PRINS, L. SANDERS, J. ZHANG, C.P. SEWTER, J. DIGBY, C.D. BYRNE, and S. O'RAHILLY. 1998. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47:1384-1391.
47. VANHARMELEN,V., S.REYNISDOTTIR, P. ERIKSSON, A.THORNE, J. HOFFSTEDT, F. LONNQVIST, and P.ARNER. 1998. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 47:913-917.
48. TSAO, T.S., H.E.MURREY, C. HUG, D.H. LEE, and H.F. LODISH. 2002. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 277:29359-29362.
49. XU, A., K.W. CHAN, R.L.HOO, Y.WANG, K.C. TAN, J.ZHANG, B. CHEN, M.C. LAM, C.TSE, G.J. COOPER, and K.S. LAM. 2005. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18073-18080.
50. OKAMOTO, Y., S. KIHARA, N. OUCHI, M. NISHIDA, Y. ARITA, M. KUMADA, K. OHASHI, N. SAKAI, I. SHIMOMURA, H. KOBAYASHI, N. TERASAKA, T. INABA, T. FUNAHASHI, and Y. MATSUZAWA. 2002. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770.
51. OUCHI, N., S.KIHARA,Y.ARITA,M.NISHIDA,A.MATSUYAMA,Y.OKAMOTO,M. ISHIGAMI,H.KURIYAMA,K. KISHIDA, H. NISHIZAWA, K. HOTTA, M. MURAGUCHI, Y. OHMOTO, S. YAMASHITA, T. FUNAHASHI, and Y. MATSUZAWA. 2001. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057-1063.
52. GOLDSTEIN, B.J., and R. SCALIA. 2004. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89:2563-2568.
53. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2002. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143-3421.
54. KUMADA, M., S.KIHARA, S. SUMITSUJI, T.KAWAMOTO, S.MATSUMOTO,N.OUCHI, Y. ARITA, Y.OKAMOTO, I. SHIMOMURA, H.HIRAOKA, T.NAKAMURA, T. FUNAHASHI, Y. MATSUZAWA, and Osaka CAD Study Group. Coronary Artery Disease. 2003. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89.
55. ZOCCALI, C., F. MALLAMACI, G. TRIPEPI, F.A. BENEDETTO, S. CUTRUPI, S. PARLONGO, L.S. MALATINO, G. BONANNO, G. SEMINARA, F. RAPISARDA, P. FATUZZO, M. BUEMI, G. NICOCIA, S. TANAKA, N. OUCHI, S. KIHARA, T. FUNAHASHI, and Y. MATSUZAWA. 2002. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141.
56. OHASHI, K., S.KIHARA,N.OUCHI,M.KUMADA, K.FUJITA, A.HIUGE, T.HIBUSE,M. RYO,H.NISHIZAWA, N. MAEDA, K. MAEDA, R. SHIBATA, K. WALSH, T. FUNAHASHI, and I. SHIMOMURA. 2006. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47:1108-1116.
57. LINDSAY, R.S., T. FUNAHASHI, R.L. HANSON, Y.MATSUZAWA, S. TANAKA, P.A. TATARANNI,W.C. KNOWLER, and J. KRAKOFF. 2002. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58.
58. SALAS-SALVADO, J., M. GRANADA, M. BULLO, A. COROMINAS, P. CASAS, and M. FOZ. 2007. Plasma adiponectin distribution in a Mediterranean population and its association with cardiovascular risk factors and metabolic syndrome. Metabolism 56:1486-1492.
59. ARITA, Y., S. KIHARA, N. OUCHI, M. TAKAHASHI, K. MAEDA, J. MIYAGAWA, K. HOTTA, I. SHIMOMURA, T. NAKAMURA, K. MIYAOKA, H. KURIYAMA, M. NISHIDA, S. YAMASHITA, K. OKUBO, K. MATSUBARA, M. MURAGUCHI, Y. OHMOTO, T. FUNAHASHI, and Y. MATSUZAWA. 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83.
60. HOTTA, K., T. FUNAHASHI, Y. ARITA, M. TAKAHASHI, M. MATSUDA, Y. OKAMOTO, H. IWAHASHI, H. KURIYAMA, N. OUCHI, K. MAEDA, M. NISHIDA, S. KIHARA, N. SAKAI, T. NAKAJIMA, K. HASEGAWA, M. MURAGUCHI, Y. OHMOTO, T. NAKAMURA, S. YAMASHITA, T. HANAFUSA, and Y. MATSUZAWA. 2000. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599.
61. OUCHI, N., S. KIHARA, Y. ARITA, K. MAEDA, H. KURIYAMA, Y. OKAMOTO, K. HOTTA, M. NISHIDA, M. TAKAHASHI, T. NAKAMURA, S. YAMASHITA, T. FUNAHASHI, and Y.MATSUZAWA. 1999. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476.
62. HOFFSTEDT, J., E. ARVIDSSON, E. SJOLIN, K. WAHLEN, and P. ARNER. 2004. Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab 89:1391-1396.
63. MOTOSHIMA, H., X. WU, M.K. SINHA, V.E. HARDY, E.L. ROSATO, D.J. BARBOT, F.E. ROSATO, and B.J. GOLDSTEIN. 2002. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662-5667.
64. FISHER, F.M., P.G. MCTERNAN, G. VALSAMAKIS, R. CHETTY, A.L. HARTE, A.J. ANWAR, J. STARCYNSKI, J. CROCKER, A.H. BARNETT, C.L. MCTERNAN, and S. KUMAR. 2002. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res 34:650-654.
65. DEGAWA-YAMAUCHI, M., K.A. MOSS, J.E. BOVENKERK, S.S. SHANKAR, C.L. MORRISON, C.J. LELLIOTT, A. VIDAL-PUIG, R. JONES, and R.V. CONSIDINE. 2005. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes Res 13:662-669.
66. STEPPAN, C.M., S.T.BAILEY, S.BHAT, E.J.BROWN, R.R.BANERJEE, C.M.WRIGHT, H.R.PATEL, R.S.AHIMA, and M.A. LAZAR. 2001. The hormone resistin links obesity to diabetes. Nature 409:307-312.
67. YANNAKOULIA, M., N.YIANNAKOURIS, S. BLUHER, A.L.MATALAS,D.KLIMIS-ZACAS, and C.S.MANTZOROS. 2003. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 88:1730-1736.
68. DEGAWA-YAMAUCHI, M., J.E. BOVENKERK, B.E. JULIAR,W.WATSON, K.KERR, R. JONES, Q.ZHU, and R.V. CONSIDINE. 2003. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 88:5452-5455.
69. AZUMA, K., F. KATSUKAWA, S. OGUCHI, M. MURATA, H. YAMAZAKI, A. SHIMADA, and T. SARUTA. 2003. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 11:997-1001.
70. STEPPAN, C.M., and M.A. LAZAR. 2002. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 13:18-23.
71. JUAN, C.C., L.C.AU,V.S. FANG, S.F.KANG,Y.H.KO, S.F.KUO, Y.P. HSU, C.F.KWOK, and L.T.HO. 2001. Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun 289:1328-1333.
72. HAUGEN, F., A. JORGENSEN, C.A. DREVON, and P. TRAYHURN. 2001. Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett 507:105-108.
73. STEPPAN, C.M., and M.A. LAZAR. 2004. The current biology of resistin. J Intern Med 255:439-447.
74. MCTERNAN, P.G., C.L. MCTERNAN, R. CHETTY, K. JENNER, F.M. FISHER, M.N. LAUER, J. CROCKER, A.H. BARNETT, and S. KUMAR. 2002. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 87:2407.
75. FAIN, J.N., P.S. CHEEMA, S.W. BAHOUTH, and M. LLOYDHILER. 2003. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 300:674-678.
76. PRADHAN, A.D., J.E. MANSON, N. RIFAI, J.E. BURING, and P.M. RIDKER. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334.
77. KERN, P.A., S. RANGANATHAN, C. LI, L. WOOD, and G. RANGANATHAN. 2001. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745-E751.
78. DANDONA, P., R. WEINSTOCK, K. THUSU, E. ABDEL-RAHMAN, A. ALJADA, and T. WADDEN. 1998. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907-2910.
79. DANDONA, P., A. ALJADA, and A. BANDYOPADHYAY. 2004. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7.
80. VOZAROVA, B., C. WEYER, K. HANSON, P.A. TATARANNI, C. BOGARDUS, and R.E. PRATLEY. 2001. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414-417.
81. RUDIN, E., and N. BARZILAI. 2005. Inflammatory peptides derived from adipose tissue. Immun Ageing 2:1.
82. HO, R.C., K.P. DAVY, M.S. HICKEY, and C.L. MELBY. 2005. Circulating tumor necrosis factor alpha is higher in non-obese, non-diabetic Mexican Americans compared to non-Hispanic white adults. Cytokine 30:14-21.
83. MOON, Y.S., D.H. KIM, and D.K. SONG. 2004. Serum tumor necrosis factor-alpha levels and components of the metabolic syndrome in obese adolescents. Metabolism 53:863-867.
84. FONTANA, L., J.C. EAGON, M.E. TRUJILLO, P.E. SCHERER, and S. KLEIN. 2007. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56:1010-1013.
85. DAS, U.N. 2005. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 11: RA155-RA162.
86. THAM, D.M., B. MARTIN-MCNULTY, Y.X.WANG, D.W.WILSON, R.VERGONA, M.E. SULLIVAN, W.DOLE, and J.C. RUTLEDGE. 2002. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 11:21-30.
87. MASSIERA, F., J. SEYDOUX, A. GELOEN, A. QUIGNARD-BOULANGE, S. TURBAN, P. SAINT-MARC, A. FUKAMIZU, R. NEGREL, G. AILHAUD, and M. TEBOUL. 2001. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 142:5220-5225.
88. BOUSTANY, C.M., K. BHARADWAJ, A. DAUGHERTY, D.R. BROWN, D.C. RANDALL, and L.A. CASSIS. 2004. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 287:R943-R949.
89. IACOBELLIS, G., M.C. RIBAUDO, F. ASSAEL, E. VECCI, C. TIBERTI, A. ZAPPATERRENO, U. DI MARIO, and F. LEONETTI. 2003. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 88:5163-5168.
90. LOHN, M., G. DUBROVSKA, B. LAUTERBACH, F.C. LUFT, M. GOLLASCH, and A.M. SHARMA. 2002. Periadventitial fat releases a vascular relaxing factor. FASEB J 16:1057-1063.
91. VERLOHREN, S., G. DUBROVSKA, S.Y. TSANG, K. ESSIN, F.C. LUFT, Y. HUANG, and M. GOLLASCH. 2004. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension 44:271-276.
92. IACOBELLIS, G., D. PISTILLI, M. GUCCIARDO, F. LEONETTI, F. MIRALDI, G. BRANCACCIO, P. GALLO, and C.R. DI GIOIA. 2005. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine 29:251-255.
93. BAKER, A.R., N.F. SILVA, D.W. QUINN, A.L. HARTE, D. PAGANO, R.S. BONSER, S. KUMAR, and P.G. MCTERNAN. 2006. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 5:1.
94. CHENG, K.H., C.S. CHU, K.T. LEE, T.H. LIN, C.C. HSIEH, C.C. CHIU, W.C. VOON, S.H. SHEU, and W.T. LAI. 2008. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes (Lond) 32:268-274.
95. CHATTERJEE, T.K., L.L. STOLL, G.M. DENNING, A. HARRELSON, A.L. BLOMKALNS, G. IDELMAN, F.G. ROTHENBERG, B. NELTNER, S.A. ROMIG-MARTIN, E.W. DICKSON, S. RUDICH, and N.L. WEINTRAUB. 2009. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res 104:541-549.
96. NEUSCHWANDER-TETRI, B.A., and S.H. CALDWELL. 2003. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37:1202-1219.
97. SHETH, S.G., F.D. GORDON, and S. CHOPRA. 1997. Nonalcoholic steatohepatitis. Ann Intern Med 126:137-145.
98. ZAFRANI, E.S. 2004. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch 444:3-12.
99. LUYCKX, F.H., P.J. LEFEBVRE, and A.J. SCHEEN. 2000. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 26:98-106.
100. MALNICK, S.D., M. BEERGABEL, and H. KNOBLER. 2003. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM 96:699-709.
101. WANLESS, I.R., and J.S. LENTZ. 1990. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12:1106-1110.
102. ANGELICO, F., M. DEL BEN, R. CONTI, S. FRANCIOSO, K. FEOLE, D. MACCIONI, T.M. ANTONINI, and C. ALESSANDRI. 2003. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 18:588-594.
103. KELLEY, D.E., T.M.MCKOLANIS, R.A.HEGAZI, L.H.KULLER, and S.C.KALHAN. 2003. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 285:E906-E916.
104. MARCHESINI, G., M. BRIZI, A.M. MORSELLI-LABATE, G. BIANCHI, E. BUGIANESI, A.J. MCCULLOUGH, G. FORLANI, and N. MELCHIONDA. 1999. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107:450-455.
105. COMERT, B., M.R. MAS, H. ERDEM, A. DINC, U. SAGLAMKAYA, M. CIGERIM, O. KUZHAN, T. UNAL, and F. KOCABALKAN. 2001. Insulin resistance in non-alcoholic steatohepatitis. Dig Liver Dis 33:353-358.
106. HSIAO, T.J., J.C. CHEN, and J.D. WANG. 2004. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 28:167-172.
107. CHURCH, T.S., J.L. KUK, R. ROSS, E.L. PRIEST, E. BILTOFT, and S.N. BLAIR. 2006. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 130:2023-2030.
108. KOTRONEN, A., L. JUURINEN, A. HAKKARAINEN, J. WESTERBACKA, A. CORNER, R. BERGHOLM, and H. YKI-JARVINEN. 2008. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31:165-169.
109. MESHKANI, R., and K.ADELI. 2009. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 42:1331-1346.
110. JENSEN, M.D. 2006. Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity (Silver Spring) 14 (Suppl 1): 20S-24S.
111. BERK, P.D. 2008. Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology 48:1362-1376.
112. RODEN, M. 2006. Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2:335-348.
113. HOTAMISLIGIL, G.S. 2006. Inflammation and metabolic disorders. Nature 444:860-867.
114. KADOWAKI, T., and T. YAMAUCHI. 2005. Adiponectin and adiponectin receptors. Endocr Rev 26:439-451.
115. KANTARTZIS, K., K. RITTIG, B. BALLETSHOFER, J. MACHANN, F. SCHICK, K. PORUBSKA, A. FRITSCHE, H.U. HARING, and N. STEFAN. 2006. The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. Clin Chem 52:1934-1942.
116. BUGIANESI, E., U. PAGOTTO, R.MANINI, E.VANNI, A.GASTALDELLI, R. DE IASIO, E.GENTILCORE, S.NATALE, M. CASSADER, M. RIZZETTO, R. PASQUALI, and G. MARCHESINI. 2005. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90:3498-3504.
117. STEFAN, N., F.MACHICAO, H. STAIGER, J. MACHANN, F. SCHICK, O. TSCHRITTER, C. SPIETH, C.WEIGERT, A. FRITSCHE, M. STUMVOLL, and H.U. HARING. 2005. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 48:2282-2291.
118. TILG, H., and A.M.DIEHL. 2000. Cytokines in alcoholic and nonalcoholic steatohepatitis.NEngl J Med 343:1467-1476.
119. LI, Z., S.YANG, H.LIN, J. HUANG, P.A.WATKINS, A.B.MOSER, C.DESIMONE, X.Y. SONG, and A.M.DIEHL. 2003. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:343-350.
120. FERNANDEZ-REAL, J.M., and W. RICART. 2003. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24:278-301.
121. XU, A., Y. WANG, H. KESHAW, L.Y. XU, K.S. LAM, and G.J. COOPER. 2003. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112:91-100.
122. AYGUN, C., O. SENTURK, S. HULAGU, S.URAZ, A.CELEBI, T. KONDUK, B. MUTLU, and Z. CANTURK. 2006. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 18:175-180.
123. PAGANO, C., G. SOARDO,W. ESPOSITO, F. FALLO, L.BASAN, D. DONNINI, G.FEDERSPIL, L.A. SECHI, and R. VETTOR. 2005. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152:113-118.
124. LOUTHAN, M.V., S. BARVE, C.J.MCCLAIN, and S. JOSHI-BARVE. 2005. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr 147:835-838.
125. ZOU, C.C., L. LIANG, F.HONG, J.F. FU, and Z.Y. ZHAO. 2005. Serum adiponectin, resistin levels and nonalcoholic fatty liver disease in obese children. Endocr J 52:519-524.
126. YAMAUCHI, T., J. KAMON, Y. MINOKOSHI, Y. ITO, H.WAKI, S. UCHIDA, S. YAMASHITA, M. NODA, S. KITA, K. UEKI, K. ETO, Y. AKANUMA, P. FROGUEL, F. FOUFELLE, P. FERRE, D. CARLING, S. KIMURA, R. NAGAI, B.B. KAHN, and T. KADOWAKI. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295.
127. JAVOR, E.D., M.G.GHANY, E.K.COCHRAN, E.A.ORAL, A.M.DEPAOLI,A.PREMKUMAR, D.E.KLEINER, and P. GORDEN. 2005. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41:753-760.
128. LEE, Y., M.Y. WANG, T. KAKUMA, Z.W. WANG, E. BABCOCK, K. MCCORKLE, M. HIGA, Y.T. ZHOU, and R.H. UNGER. 2001. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem 276:5629-5635.
129. ANDREELLI, F., M. FORETZ, C. KNAUF, P.D. CANI, C. PERRIN, M.A. IGLESIAS, B. PILLOT, A. BADO, F. TRONCHE, G. MITHIEUX, S. VAULONT, R. BURCELIN, and B. VIOLLET. 2006. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 147:2432-2441.
130. SINGH, A., M.WIRTZ, N. PARKER, M. HOGAN, J. STRAHLER, G.MICHAILIDIS, S. SCHMIDT, A.VIDAL-PUIG, S. DIANO, P. ANDREWS, M.D. BRAND, and J. FRIEDMAN. 2009. Leptin-mediated changes in hepatic mitochondrial metabolism, structure, and protein levels. Proc Natl Acad Sci USA 106:13100-13105.
131. SINGHAL, N.S., R.T. PATEL, Y. QI, Y.S. LEE, and R.S. AHIMA. 2008. Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice. Am J Physiol Endocrinol Metab 295: E331-E338.
132. BERTOLANI, C., and F. MARRA. 2008. The role of adipokines in liver fibrosis. Pathophysiology 15:91-101.
133. KAMADA, Y., S. TAMURA, S. KISO, H. MATSUMOTO, Y. SAJI, Y. YOSHIDA, K. FUKUI, N. MAEDA, H. NISHIZAWA, H. NAGARETANI, Y. OKAMOTO, S. KIHARA, J. MIYAGAWA, Y. SHINOMURA, T. FUNAHASHI, and Y. MATSUZAWA. 2003. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125:1796-1807.
134. PAGANO, C., G. SOARDO, C. PILON, C. MILOCCO, L. BASAN, G. MILAN, D. DONNINI, D. FAGGIAN, M. MUSSAP, M. PLEBANI, C. AVELLINI, G. FEDERSPIL, L.A. SECHI, and R. VETTOR. 2006. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 91:1081-1086.
135. LEE, J.S., S.H. KIM, D.W. JUN, J.H. HAN, E.C. JANG, J.Y. PARK, B.K. SON, S.H. KIM, Y.J. JO, Y.S. PARK, and Y.S. KIM. 2009. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol 15:1869-1875.
136. TUSHUIZEN, M.E., M.C. BUNCK, P.J. POUWELS, S. BONTEMPS, J.H. VAN WAESBERGHE, R.K. SCHINDHELM, A.MARI, R.J. HEINE, and M. DIAMANT. 2007. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care 30:2916-2921.
137. SAISHO, Y., A.E. BUTLER, and P.C. BUTLER. 2008. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes: response to Tushuizen et al. Diabetes Care 31:e38; author reply e39.
138. CAMASTRA, S., M. MANCO, A. MARI, S. BALDI, A. GASTALDELLI, A.V. GRECO, G. MINGRONE, and E. FERRANNINI. 2005. Beta-cell function in morbidly obese subjects during free living: long-term effects of weight loss. Diabetes 54:2382-2389.
139. SAISHO, Y., A.E. BUTLER, J.J.MEIER, T. MONCHAMP,M. ALLEN-AUERBACH, R.A. RIZZA, and P.C. BUTLER. 2007. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat 20:933-942.
140. YIN,W., D. LIAO, M. KUSUNOKI, S.XI, K. TSUTSUMI, Z. WANG, X. LIAN, T.KOIKE, J. FAN, Y. YANG, and C. TANG. 2004. NO-1886 decreases ectopic lipid deposition and protects pancreatic beta cells in dietinduced diabetic swine. J Endocrinol 180:399-408.
141. WADE, T.E., A.MATHUR, D.LU, D.A. SWARTZ-BASILE, H.A. PITT, and N.J. ZYROMSKI. 2009. Adiponectin receptor-1 expression is decreased in the pancreas of obese mice. J Surg Res 154:78-84.
142. TUDURI, E., L. MARROQUI, S. SORIANO, A.B. ROPERO, T.M. BATISTA, S. PIQUER, M.A. LOPEZ-BOADO, E.M. CARNEIRO, R. GOMIS, A.NADAL, and I. QUESADA. 2009. Inhibitory effects of leptin on pancreatic alpha-cell function. Diabetes 58:1616-1624.
143. ADRYCH, K., M. SMOCZYNSKI, E. STELMANSKA, J. KORCZYNSKA, E. GOYKE, and J. SWIERCZYNSKI. 2008. Serum adiponectin and leptin concentrations in patients with chronic pancreatitis of alcoholic and nonalcoholic origin. Pancreas 36:120-124.
144. ZYROMSKI, N.J., A. MATHUR, H.A. PITT, D. LU, J.T. GRIPE, J.J. WALKER, K. YANCEY, T.E. WADE, and D.A. SWARTZ-BASILE. 2008. A murine model of obesity implicates the adipokine milieu in the pathogenesis of severe acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 295:G552-G558.
145. CHEN, H.C., J.D. ROTH, B.E. SCHROEDER, and C. WEYER. 2008. Role of islet-, gut-, and adipocytederived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy. Curr Diabetes Rev 4:79-91.
146. ROTH, J.D., B.L. ROLAND, R.L. COLE, J.L. TREVASKIS, C. WEYER, J.E. KODA, C.M. ANDERSON, D.G. PARKES, andA.D.BARON. 2008. Leptin responsiveness restored by amylin agonismin diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 105:7257-7262.
147. DESPRES, J.P., I. LEMIEUX, J. BERGERON, P. PIBAROT, P. MATHIEU, E. LAROSE, J. RODES-CABAU, O.F. BERTRAND, and P. POIRIER. 2008. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 28:1039-1049.
148. KALRA, S.P. 2008. Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: new therapeutic approaches. Nutrition 24:820-826.
149. KALRA, S.P. 2007. Global life-long health benefits of repression of hypothalamic NPY system by central leptin gene therapy. Curr Top Med Chem 7:1675-1681.
150. GUO, K., J.E. MCMINN, T. LUDWIG, Y.H. YU, G. YANG, L. CHEN, D. LOH, C. LI, S. CHUA, JR., AND Y. ZHANG. 2007.DISRUPTION OF PERIPHERAL LEPTIN SIGNALING IN MICE RESULTS IN HYPERLEPTINEMIA WITHOUT ASSOCIATED METABOLIC ABNORMALITIES. ENDOCRINOLOGY 148:3987-3997.
151. MARATOS-FLIER, E. 2008. The long reach of leptin. Nat Med 14:604-606.
152. CONE, R.D., M.A. COWLEY, A.A. BUTLER, W. FAN, D.L. MARKS, and M.J. LOW. 2001. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 25 (Suppl 5): S63-S67.
153. GONG, L., F. YAO, K. HOCKMAN, H.H. HENG, G.J. MORTON, K. TAKEDA, S. AKIRA, M.J. LOW, M. RUBINSTEIN, and R.G. MACKENZIE. 2008. Signal transducer and activator of transcription-3 is required in hypothalamic agouti-related protein/neuropeptide Y neurons for normal energy homeostasis. Endocrinology 149:3346-3354.
154. PERRINI, S., A. LEONARDINI, L. LAVIOLA, and F. GIORGINO. 2008. Biological specificity of visceral adipose tissue and therapeutic intervention. Arch Physiol Biochem 114:277-286.
155. CARR, T.P., E.D. JESCH, and A.W. BROWN. 2008. Endocannabinoids, metabolic regulation, and the role of diet. Nutr Res 28:641-650.
156. DI MARZO, V. 2008. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51:1356-1367.
157. GASPERI, V., F. FEZZA, N. PASQUARIELLO, M. BARI, S. ODDI, A.F. AGRO, and M. MACCARRONE. 2007. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 64:219-229.
158. GARY-BOBO, M., G. ELACHOURI, B. SCATTON, G. LE FUR, F. OURY-DONAT, and M. BENSAID. 2006. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69:471-478.
159. MATIAS, I., M.P. GONTHIER, P. ORLANDO, V.MARTIADIS, L. DE PETROCELLIS, C. CERVINO, S. PETROSINO, L. HOAREAU, F. FESTY, R. PASQUALI, R. ROCHE, M. MAJ, U. PAGOTTO, P. MONTELEONE, and V. DI MARZO. 2006. Regulation, function, and dysregulation of endocannabinoids in models of adipose and betapancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91:3171-3180.
160. DIMARZO,V., S.K.GOPARAJU, L.WANG, J.LIU, S. BATKAI, Z. JARAI, F. FEZZA, G.I.MIURA, R.D. PALMITER, T. SUGIURA, and G.KUNOS. 2001. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825.
161. SCHERER, T., and C. BUETTNER. 2009. The dysregulation of the endocannabinoid system in diabesity- a tricky problem. J Mol Med 87:663-668.
162. RAVINET TRILLOU, C., C. DELGORGE, C. MENET, M. ARNONE, and P. SOUBRIE. 2004. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648.
163. WIERZBICKI, A.S. 2006. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 60:1697-1706.
164. ALEXANDER, C.M., P.B. LANDSMAN, S.M. TEUTSCH, S.M.HAFFNER, Third National Health and Nutrition Examination Survey (NHANES III), and National Cholesterol Education Program (NCEP). 2003. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52:1210-1214.
165. CHAIT, A., and K.E. BORNFELDT. 2009. Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res 50 (Suppl): S335-S339.
166. HAMMOUD, T., J.F. TANGUAY, and M.G. BOURASSA. 2000. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 36:355-365.
167. QIAO, Q., W. GAO, L. ZHANG, R. NYAMDORJ, and J. TUOMILEHTO. 2007. Metabolic syndrome and cardiovascular disease. Ann Clin Biochem 44:232-263.
168. POIRIER, P. 2008. Targeting abdominal obesity in cardiology: can we be effective? Can J Cardiol 24 (Suppl D): 13D-17D.
169. HEIDT, M.C., M. VICIAN, S.K. STRACKE, T. STADLBAUER, M.T. GREBE, A. BOENING, P.R. VOGT, and A. ERDOGAN. 2009. Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg 57:276-280.
170. KRALISCH, S., G. SOMMER, V. STANGL, U. KOHLER, J. KRATZSCH, H. STEPAN, R. FABER, A. SCHUBERT, U. LOSSNER, A. VIETZKE, M. BLUHER, M. STUMVOLL, and M. FASSHAUER. 2008. Secretory products from human adipocytes impair endothelial function via nuclear factor kappaB. Atherosclerosis 196:523-531.
171. SATTAR, N., G. WANNAMETHEE, N. SARWAR, J. TCHERNOVA, L. CHERRY, A.M. WALLACE, J. DANESH, and P.H.WHINCUP. 2006. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114:623-629.
172. SATTAR, N., G. WANNAMETHEE, N. SARWAR, J. CHERNOVA, D.A. LAWLOR, A. KELLY, A.M. WALLACE, J. DANESH, and P.H.WHINCUP. 2009. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol 53:167-175.
173. LIEB,W., L.M. SULLIVAN, J.ARAGAM, T.B.HARRIS, R. ROUBENOFF, E.J. BENJAMIN, and R.S.VASAN. 2009. Relation of serum leptin with cardiac mass and left atrial dimension in individuals >70 years of age. Am J Cardiol 104:602-605.
174. WELSH, P., H.M. MURRAY, B.M. BUCKLEY, A.J. DE CRAEN, I. FORD, J.W. JUKEMA, P.W. MACFARLANE, C.J. PACKARD, D.J. STOTT, R.G. WESTENDORP, J. SHEPHERD, and N. SATTAR. 2009. Leptin predicts diabetes but not cardiovascular disease: results from a large prospective study in an elderly population. Diabetes Care 32:308-310.
175. FANTUZZI, G., and T. MAZZONE. 2007. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 27:996-1003.
176. ANDERSSON, C.X., B. GUSTAFSON, A. HAMMARSTEDT, S. HEDJAZIFAR, and U. SMITH. 2008. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab Res Rev 24:595-603.
177. MAZZONE, T. 2007. Adipose tissue and the vessel wall. Curr Drug Targets 8:1190-1195.
178. COLEMAN, D.L. 1973. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 9:294-298.
179. AIZAWA-ABE, M., Y. OGAWA, H. MASUZAKI, K. EBIHARA, N. SATOH, H. IWAI, N. MATSUOKA, T. HAYASHI, K.HOSODA, G. INOUE, Y.YOSHIMASA, and K.NAKAO. 2000. Pathophysiological role of leptin in obesityrelated hypertension. J Clin Invest 105:1243-1252.
180. SCHROETER, M.R., J. SCHNEIDERMAN, B. SCHUMANN, R. GLUCKERMANN, P. GRIMMAS, A.B. BUCHWALD, T. TIRILOMIS, F.A. SCHONDUBE, S.V. KONSTANTINIDES, and K. SCHAFER. 2007. Expression of the leptin receptor in different types of vascular lesions. Histochem Cell Biol 128:323-333.
181. GLASOW, A.,W. KIESS, U. ANDEREGG, A. BERTHOLD, A.BOTTNER, and J. KRATZSCH. 2001. Expression of leptin (Ob) and leptin receptor (Ob-R) in human fibroblasts: regulation of leptin secretion by insulin. J Clin Endocrinol Metab 86:4472-4479.
182. RESELAND, J.E., U. SYVERSEN, I. BAKKE, G. QVIGSTAD, L.G. EIDE, O. HJERTNER, J.O. GORDELADZE, and C.A. DREVON. 2001. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res 16:1426-1433.
183. REYES, M.R., B. LAZALDE, F.A. POSADAS DEL RIO, and B. ESCALANTE. 2008. Identification of leptin gene expression in sinusoidal endothelial rat liver cells. Endothelium 15:121-125.
184. KNUDSON, J.D., U.D. DINCER, C. ZHANG, A.N. SWAFFORD JR, R. KOSHIDA, A. PICCHI, M. FOCARDI, G.M. DICK, and J.D. TUNE. 2005. Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol Heart Circ Physiol 289:H48-H56.
185. GOETZE, S., A. BUNGENSTOCK, C. CZUPALLA, F. EILERS, P. STAWOWY, U. KINTSCHER, C. SPENCER-HANSCH, K. GRAF, B. NURNBERG, R.E. LAW, E. FLECK, and M. GRAFE. 2002. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 40:748-754.
186. ZEIDAN, A., and M. KARMAZYN. 2006. Leptin and vascular smooth muscle. Curr Vasc Pharmacol 4:383-393.
187. SCHNEIDERMAN, J., A.J. SIMON, M.R. SCHROETER, M.Y. FLUGELMAN, S. KONSTANTINIDES, and K. SCHAEFER. 2008. Leptin receptor is elevated in carotid plaques from neurologically symptomatic patients and positively correlated with augmented macrophage density. J Vasc Surg 48:1146-1155.
188. REYNOLDS, K., and R.P. WILDMAN. 2009. Update on the metabolic syndrome: hypertension. Curr Hypertens Rep 11:150-155.
189. AUCOTT, L., H. ROTHNIE, L. MCINTYRE, M. THAPA, C. WAWERU, and D. GRAY. 2009. Long-term weight loss from lifestyle intervention benefits blood pressure?: a systematic review. Hypertension 54:756-762.
190. PATEL, J.V., H.S. LIM, K. DUBB, E.A. HUGHES, and G.Y. LIP. 2009. Circulating levels of adiponectin, leptin, and tumour necrosis factor alpha in hypertension. Ann Med 41:291-300.
191. CROWLEY, V.E. 2008. Overview of human obesity and central mechanisms regulating energy homeostasis. Ann Clin Biochem 45:245-255.
192. MATSUMURA, K., T. TSUCHIHASHI, K. FUJII, and M. IIDA. 2003. Neural regulation of blood pressure by leptin and the related peptides. Regul Pept 114:79-86.
193. BRYDON, L., K. O'DONNELL, C.E. WRIGHT, A.J. WAWRZYNIAK, J. WARDLE, and A. STEPTOE. 2008. Circulating leptin and stress-induced cardiovascular activity in humans. Obesity (Silver Spring) 16:2642-2647.
194. TANIDA, M., K. NAGAI, and H. KANEKO. 2003. Activation of the renal sympathetic nerve by leptin microinjection into the ventromedial hypothalamus in rats. In Vivo 17:213-217.
195. POLAK, J. 2008. Multiple roles of leptin in blood pressure regulation, from central to peripheral mechanisms. Am J Hypertens 21:1172.
196. ZEIDAN,A.,D.M.PURDHAM,V.RAJAPUROHITAM,S.JAVADOV,S.CHAKRABARTI,andM.KARMAZYN.2005.Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J Pharmacol Exp Ther 315:1075-1084.
197. ODA, A., T. TANIGUCHI, and M. YOKOYAMA. 2001. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 47:141-150.
198. BOHLEN, F., J. KRATZSCH, M. MUELLER, B. SEIDEL, M. FRIEDMAN-EINAT, H. WITZIGMANN, D. TEUPSER, A. KOERNER, M. STORCK, and J. THIERY. 2007. Leptin inhibits cell growth of human vascular smooth muscle cells. Vascul Pharmacol 46:67-71.
199. PROCOPIO, C., F.ANDREOZZI, E. LARATTA,A. CASSESE, F. BEGUINOT, F.ARTURI, M.L.HRIBAL, F. PERTICONE, and G. SESTI. 2009. Leptin-stimulated endothelial nitric-oxide synthase via an adenosine 50-monophosphate- activated protein kinase/Akt signaling pathway is attenuated by interaction with C-reactive protein. Endocrinology 150:3584-3593.
200. RODRIGUEZ, A., G. FRUHBECK, J. GOMEZ-AMBROSI, V. CATALAN, N. SAINZ, J. DIEZ, G. ZALBA, and A. FORTUNO. 2006. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. J Hypertens 24:1589-1597.
201. RODRIGUEZ, A., A. FORTUNO, J. GOMEZ-AMBROSI, G. ZALBA, J. DIEZ, and G. FRUHBECK. 2007. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. Endocrinology 148:324-331.
202. KORDA, M., R. KUBANT, S. PATTON, and T. MALINSKI. 2008. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 295:H1514-H1521.
203. FORSTERMANN, U., and T. MUNZEL. 2006. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113:1708-1714.
204. MA, D., M.F. FEITOSA, J.B. WILK, J.M. LARAMIE, K. YU, C. LEIENDECKER-FOSTER, R.H. MYERS, M.A. PROVINCE, and I.B.BORECKI. 2009. Leptin is associated with blood pressure and hypertension in women from the National Heart, Lung, and Blood Institute Family Heart Study. Hypertension 53:473-479.
205. THOMOPOULOS, C., D.P. PAPADOPOULOS, O. PAPAZACHOU, A. BRATSAS, S. MASSIAS, G. ANASTASIADIS, D. PERREA, and T. MAKRIS. 2009. Free leptin is associated with masked hypertension in nonobese subjects: a cross-sectional study. Hypertension 53:965-972.
206. STRAZNICKY, N.E., N. EIKELIS, E.A. LAMBERT, and M.D. ESLER. 2008. Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep 10:440-447.
207. GRASSI, G. 2006. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res 29:839-847.
208. MANCIA, G., P. BOUSQUET, J.L. ELGHOZI, M.ESLER, G. GRASSI, S. JULIUS, J.REID, and P.A. VAN ZWIETEN. 2007. The sympathetic nervous system and the metabolic syndrome. J Hypertens 25:909-920.
209. ARNOLD, A.C., H.A. SHALTOUT, P.E. GALLAGHER, and D.I. DIZ. 2009. Leptin impairs cardiovagal baroreflex function at the level of the solitary tract nucleus. Hypertension 54:1001-1008.
210. KNUDSON, J.D., U.D. DINCER, G.M. DICK, H. SHIBATA, R. AKAHANE, M. SAITO, and J.D. TUNE. 2005. Leptin resistance extends to the coronary vasculature in prediabetic dogs and provides a protective adaptation against endothelial dysfunction. Am J Physiol Heart Circ Physiol 289: H1038-H1046.
211. CAI, X. 2006. Regulation of smooth muscle cells in development and vascular disease: current therapeutic strategies. Expert Rev Cardiovasc Ther 4:789-800.
212. SHAN, J., T.B. NGUYEN, H. TOTARY-JAIN, H. DANSKY, S.O. MARX, and A.R. MARKS. 2008. Leptinenhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proc Natl Acad Sci USA 105:19006-19011.
213. LLOYD, D.J., J. MCCORMICK, J. HELMERING, K.W. KIM, M. WANG, P. FORDSTROM, S.A. KAUFMAN, R.A. LINDBERG, and M.M.VENIANT. 2008. Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr. Am J Physiol Endocrinol Metab 294:E496-E505.
214. NAIR, P., K. RADFORD, A. FANAT, L.J. JANSSEN, M. PETERS-GOLDEN, and P.G. COX. 2008. The effects of leptin on airway smooth muscle responses. Am J Respir Cell Mol Biol 39:475-481.
215. BODARY, P.F., Y. SHEN, M. OHMAN, K.L. BAHROU, F.B. VARGAS, S.S. CUDNEY, K.J. WICKENHEISER, M.G. MYERS, JR., AND D.T. EITZMAN. 2007. LEPTIN REGULATES NEOINTIMA FORMATION AFTER ARTERIAL INJURY THROUGH MECHANISMS INDEPENDENT OF BLOOD PRESSURE AND THE LEPTIN RECEPTOR/STAT3 SIGNALING PATHWAYS INVOLVED IN ENERGY BALANCE. ARTERIOSCLER THROMB VASC BIOL 27:70-76.
216. DUBEY, L., and Z. HESONG. 2006. Role of leptin in atherogenesis. Exp Clin Cardiol 11:269-275.
217. KAZUMI, T., A. KAWAGUCHI, T. HIRANO, and G. YOSHINO. 2003. C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism 52:1113-1116.
218. INOUE, N. 2006. Vascular C-reactive protein in the pathogenesis of coronary artery disease: role of vascular inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets 6:227-231.
219. CORSONELLO, A., and F. CORICA. 2008. Leptin, obesity and platelet responsiveness: another piece in the puzzle. Thromb Haemost 100:960-961.
220. NAKATA, M., T. YADA, N. SOEJIMA, and I. MARUYAMA. 1999. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 48:426-429.
221. CORSONELLO, A., A. MALARA, D. DE DOMENICO, F. PERTICONE, A. VALENTI, M. BUEMI, R. IENTILE, and F. CORICA. 2004. Identifying pathways involved in leptin-dependent aggregation of human platelets. Int J Obes Relat Metab Disord 28:979-984.
222. DELLAS, C., K. SCHAFER, I. ROHM, M. LANKEIT, T. ELLROTT, V. FAUSTIN, J. RIGGERT, G. HASENFUSS, and S. KONSTANTINIDES. 2008. Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity. Thromb Haemost 100:1123-1129.
223. TALAVERA-ADAME, D., Y. XIONG, T. ZHAO, A.E. ARIAS, M.R. SIERRA-HONIGMANN, and D.L. FARKAS. 2008. Quantitative and morphometric evaluation of the angiogenic effects of leptin. J Biomed Opt 13:064017.
224. ANAGNOSTOULIS, S., A.J. KARAYIANNAKIS, M. LAMBROPOULOU, A. EFTHIMIADOU, A. POLYCHRONIDIS, and C. SIMOPOULOS. 2008. Human leptin induces angiogenesis in vivo. Cytokine 42:353-357.
225. PARK, H.Y., H.M. KWON, H.J. LIM, B.K. HONG, J.Y. LEE, B.E. PARK, Y. JANG, S.Y. CHO, and H.S. KIM. 2001. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 33:95-102.
226. RUTKOWSKI, J.M., K.E.DAVIS, and P.E. SCHERER. 2009. Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. FEBS J 276:5738-5746.
227. YAMAUCHI, T., J. KAMON, H.WAKI, Y. IMAI, N. SHIMOZAWA, K. HIOKI, S.UCHIDA, Y. ITO, K. TAKAKUWA, J. MATSUI, M. TAKATA, K. ETO, Y. TERAUCHI, K. KOMEDA, M. TSUNODA, K. MURAKAMI, Y. OHNISHI, T. NAITOH, K. YAMAMURA, Y. UEYAMA, P. FROGUEL, S. KIMURA, R. NAGAI, and T. KADOWAKI. 2003. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468.
228. CAO, Y., L. TAO, Y. YUAN, X. JIAO, W.B. LAU, Y. WANG, T. CHRISTOPHER, B. LOPEZ, L. CHAN, B. GOLDSTEIN, and X.L.MA. 2009. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 46:413-419.
229. WOLF, A.M., D.WOLF, M.A. AVILA, A.R.MOSCHEN, C. BERASAIN, B. ENRICH, H. RUMPOLD, and H. TILG. 2006. Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatol 44:537-543.
230. CORBETTA, S., G. BULFAMANTE, D. CORTELAZZI, V. BARRESI, I. CETIN, G. MANTOVANI, S. BONDIONI, P. BECK-PECCOZ, and A. SPADA. 2005. Adiponectin expression in human fetal tissues during mid- and late gestation. J Clin Endocrinol Metab 90:2397-2402.
231. TAKAOKA, M., D. NAGATA, S. KIHARA, I. SHIMOMURA, Y. KIMURA, Y.TABATA, Y. SAITO, R. NAGAI, and M. SATA. 2009. Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ Res 105:906-911.
232. TAKEUCHI, T.,Y.ADACHI, Y.OHTSUKI, and M. FURIHATA. 2007. Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease. Med Mol Morphol 40:115-120.
233. ZHANG, P., Y. WANG, Y. FAN, Z. TANG, and N. WANG. 2009. Overexpression of adiponectin receptors potentiates the antiinflammatory action of subeffective dose of globular adiponectin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 29:67-74.
234. CAO, J., G. DRUMMOND, K. INOUE, K. SODHI, X.Y. LI, and S. OMURA. 2008. Upregulation of heme oxygenase-1 combined with increased adiponectin lowers blood pressure in diabetic spontaneously hypertensive rats through a reduction in endothelial cell dysfunction, apoptosis and oxidative stress. Int J Mol Sci 9:2388-2406.
235. FESUS, G., G. DUBROVSKA, K. GORZELNIAK, R. KLUGE, Y. HUANG, F.C. LUFT, and M. GOLLASCH. 2007. Adiponectin is a novel humoral vasodilator. Cardiovasc Res 75:719-727.
236. ERINGA, E.C., W. BAKKER, Y.M. SMULDERS, E.H. SERNE, J.S. YUDKIN, and C.D. STEHOUWER. 2007. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation 14:389-402.
237. GALVEZ-PRIETO, B., G. DUBROVSKA, M.V. CANO, M. DELGADO, I. ARANGUEZ, M.C. GONZALEZ, M. RUIZGAYO, M. GOLLASCH, and M.S. FERNANDEZ-ALFONSO. 2008. A reduction in the amount and anticontractile effect of periadventitial mesenteric adipose tissue precedes hypertension development in spontaneously hypertensive rats. Hypertens Res 31:1415-1423.
238. TANIDA, M., J. SHEN, Y. HORII, M. MATSUDA, S. KIHARA, T. FUNAHASHI, I. SHIMOMURA, H. SAWAI, Y. FUKUDA, Y.MATSUZAWA, and K. NAGAI. 2007. Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med (Maywood) 232:390-397.
239. GOLDSTEIN, B.J., R.G. SCALIA, and X.L. MA. 2009. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 6:27-35.
240. SHIBATA, R., N. OUCHI, and T. MUROHARA. 2009. Adiponectin and cardiovascular disease. Circ J 73:608-614.
241. BELTOWSKI, J., A. JAMROZ-WISNIEWSKA, and S. WIDOMSKA. 2008. Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 8:7-46.
242. HAN, S.H., I. SAKUMA, E.K. SHIN, and K.K. KOH. 2009. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis 52:126-140.
243. OUEDRAOGO, R., X.WU, S.Q.XU, L. FUCHSEL,H.MOTOSHIMA,K.MAHADEV,K.HOUGH, R. SCALIA, and B. J. GOLDSTEIN. 2006. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 55:1840-1846.
244. BAJNOK, L., E. CSONGRADI, I. SERES, Z. VARGA, S. JEGES, A. PETI, Z. KARANYI, A. JUHASZ, E. MEZOSI, E.V.NAGY, and G. PARAGH. 2008. Relationship of adiponectin to serum paraoxonase 1. Atherosclerosis 197:363-367.
245. LESCAI, F., F. MARCHEGIANI, and C. FRANCESCHI. 2009. PON1 is a longevity gene: results of a metaanalysis. Ageing Res Rev 8:277-284.
246. VANHOUTTE, P.M., H. SHIMOKAWA, E.H. TANG, and M. FELETOU. 2009. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 196:193-222.
247. DENG, G., Y. LONG, Y.R. YU, and M.R. LI. 2010. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS pathway. Int J Obes (Lond) 34:165-171.
248. BIAN, K., M.F. DOURSOUT, and F.MURAD. 2008. Vascular system: role of nitric oxide in cardiovascular diseases. J Clin Hypertens (Greenwich) 10:304-310.
249. ZHU,W., K.K. CHENG, P.M. VANHOUTTE, K.S. LAM, and A. XU. 2008. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 114:361-374.
250. MOTOBAYASHI, Y., Y. IZAWA-ISHIZAWA, K. ISHIZAWA, S. ORINO, K.YAMAGUCHI, K.KAWAZOE, S.HAMANO, K. TSUCHIYA, S. TOMITA, and T. TAMAKI. 2009. Adiponectin inhibits insulin-like growth factor-1- induced cell migration by the suppression of extracellular signal-regulated kinase 1/2 activation, but not Akt in vascular smooth muscle cells. Hypertens Res 32:188-193.
251. MATSUDA, M., I. SHIMOMURA, M. SATA, Y. ARITA, M. NISHIDA, N. MAEDA, M. KUMADA, Y. OKAMOTO, H. NAGARETANI, H.NISHIZAWA, K.KISHIDA, R. KOMURO, N.OUCHI, S. KIHARA, R. NAGAI, T. FUNAHASHI, and Y. MATSUZAWA. 2002. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487-37491.
252. KUBOTA, N., Y. TERAUCHI, T. YAMAUCHI, T. KUBOTA, M. MOROI, J. MATSUI, K. ETO, T. YAMASHITA, J. KAMON, H. SATOH, W. YANO, P. FROGUEL, R. NAGAI, S. KIMURA, T. KADOWAKI, and T. NODA. 2002. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866.
253. LUO, X.H., L.L. ZHAO, L.Q. YUAN, M. WANG, H. XIE, and E.Y. LIAO. 2009. Development of arterial calcification in adiponectin-deficient mice: adiponectin regulates arterial calcification. J Bone Miner Res 24:1461-1468.
254. LI, R.,W.Q.WANG, H. ZHANG, X. YANG, Q. FAN, T.A. CHRISTOPHER, B.L. LOPEZ, L. TAO, B.J.GOLDSTEIN, F. GAO, and X.L. MA. 2007. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab 293:E1703-E1708.
255. KATO, H., H. KASHIWAGI, M.SHIRAGA, S.TADOKORO, T. KAMAE, H. UJIIE, S.HONDA, S.MIYATA, Y. IJIRI, J. YAMAMOTO, N.MAEDA, T. FUNAHASHI, Y.KURATA, I. SHIMOMURA, Y. TOMIYAMA, and Y.KANAKURA. 2006. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 26:224-230.
256. STEJSKAL, D., J. PROSKOVA, and P. SOLICHOVA. 2006. Adiponectin added into the plasma of healthy probands does not affect platelet aggregability. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150:89-90.
257. NATAL, C., P.RESTITUTO, C. INIGO, I.COLINA, J.DIEZ, and N.VARO. 2008. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. J Clin Endocrinol Metab 93:2319-2327.
258. RIBA, R., C.E. HUGHES, A. GRAHAM, S.P. WATSON, and K.M. NASEEM. 2008. Globular adiponectin induces platelet activation through the collagen receptor GPVI-Fc receptor gamma chain complex. J Thromb Haemost 6:1012-1020.
259. MOUQUET, F., F.CUILLERET, S. SUSEN,K.SAUTIERE, P.MARBOEUF, P.V.ENNEZAT, E.MCFADDEN, P.PIGNY, F. RICHARD, B.HENNACHE, M.C.VANTYGHEM,M. BERTRAND, J. DALLONGEVILLE, B. JUDE, and E.VANBELLE. 2009. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J 30:840-849.
260. SOYDINC, S., V. DAVUTOGLU, and I. SARI. 2007. High serum levels of adiponectin improve coronary collateral development in patients with coronary artery disease. Tohoku J Exp Med 211:347-352.
261. MAHADEV, K., X. WU, S. DONNELLY, R. OUEDRAOGO, A.D. ECKHART, and B.J. GOLDSTEIN. 2008. Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells. Cardiovasc Res 78:376-384.
262. OHASHI, K., N.OUCHI, K.SATO, A. HIGUCHI, T.O. ISHIKAWA, H.R.HERSCHMAN, S. KIHARA, and K.WALSH. 2009. Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2- dependent mechanism. Mol Cell Biol 29:3487-3499.
263. KONDO, M., R. SHIBATA, R. MIURA, M. SHIMANO, K. KONDO, P. LI, T. OHASHI, S. KIHARA, N.MAEDA, K. WALSH, N. OUCHI, and T. MUROHARA. 2009. Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. J Biol Chem 284:1718-1724.
264. NAKAMURA, N., K. NARUSE, T. MATSUKI, Y. HAMADA, E. NAKASHIMA, H. KAMIYA, T. MATSUBARA, A. ENOMOTO, M. TAKAHASHI, Y. OISO, and J. NAKAMURA. 2009. Adiponectin promotes migration activities of endothelial progenitor cells via Cdc42/Rac1. FEBS Lett 583:2457-2463.
265. BAJNOK, L., I. SERES, Z. VARGA, S. JEGES, A. PETI, Z. KARANYI, A. JUHASZ, E. CSONGRADI, E. MEZOSI, E.V. NAGY, and G. PARAGH. 2008. Relationship of serum resistin level to traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index. Exp Clin Endocrinol Diabetes 116:592-599.
266. UTZSCHNEIDER, K.M., D.B. CARR, J. TONG, T.M.WALLACE, R.L. HULL, S.ZRAIKA, Q. XIAO, J.S.MISTRY, B.M. RETZLAFF, R.H. KNOPP, and S.E. KAHN. 2005. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 48:2330-2333.
267. WANG, B.W., H. CHANG, and K.G. SHYU. 2009. Regulation of resistin by cyclic mechanical stretch in cultured rat vascular smooth muscle cell. Clin Sci (Lond) 118 (3): 221-230.
268. HUNG, H.F., B.W. WANG, H. CHANG, and K.G. SHYU. 2008. The molecular regulation of resistin expression in cultured vascular smooth muscle cells under hypoxia. J Hypertens 26:2349-2360.
269. TAKATA, Y., H. OSAWA, M. KURATA, M. KUROKAWA, J. YAMAUCHI, M. OCHI, W. NISHIDA, T. OKURA, J.HIGAKI, and H.MAKINO. 2008. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 51:534-539.
270. GENTILE, M.T., C. VECCHIONE, G. MARINO, A. ARETINI, A. DI PARDO, G. ANTENUCCI, A. MAFFEI, G. CIFELLI, L. IORIO, A. LANDOLFI, G. FRATI, and G. LEMBO. 2008. Resistin impairs insulin-evoked vasodilation. Diabetes 57:577-583.
271. FILKOVA, M., M. HALUZIK, S. GAY, and L. SENOLT. 2009. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 133:157-170.
272. SOMMER, G., S. KRALISCH, V. STANGL, A. VIETZKE, U. KOHLER, H. STEPAN, R. FABER, A. SCHUBERT, U. LOSSNER, M. BLUHER, M. STUMVOLL, and M. FASSHAUER. 2009. Secretory products from human adipocytes stimulate proinflammatory cytokine secretion from human endothelial cells. J Cell Biochem 106:729-737.
273. JIANG, C., H. ZHANG, W. ZHANG, W. KONG, Y. ZHU, H. ZHANG, Q. XU, Y. LI, and X. WANG. 2009. Homocysteine promotes vascular smooth muscle cell migration by induction of the adipokine resistin. Am J Physiol Cell Physiol 297:C1466-C1476.
274. GARTEN, A., S. PETZOLD, A. KORNER, S. IMAI, and W. KIESS. 2009. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 20:130-138.
275. BO, S., G. CICCONE, I. BALDI, R. GAMBINO, C. MANDRILE, M. DURAZZO, L. GENTILE, M. CASSADER, P. CAVALLO-PERIN, and G. PAGANO. 2009. Plasma visfatin concentrations after a lifestyle intervention were directly associated with inflammatory markers. Nutr Metab Cardiovasc Dis 19:423-430.
276. LIN, C.C., M.M. LAI, T.C. LI, C.I. LI, C.S. LIU, C.C. CHEN, and M.T.WU. 2009. Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome. Diabetes Res Clin Pract 85:24-29.
277. ARAKI, S., K. DOBASHI, K. KUBO, R. KAWAGOE, Y. YAMAMOTO, Y. KAWADA, K. ASAYAMA, and A. SHIRAHATA. 2008. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 16:384-388.
278. IMAI, S. 2009. The NADWorld: a new systemic regulatory network for metabolism and aging-Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem Biophys 53:65-74.
279. GONZALEZ, C.R., J.E. CAMINOS, M.J. VAZQUEZ, M.F. GARCES, L.A. CEPEDA, A. ANGEL, A.C. GONZALEZ, M.E. GARCIA-RENDUELES, S. SANGIAO-ALVARELLOS, M. LOPEZ, S.B. BRAVO, R. NOGUEIRAS, and C. DIEGUEZ. 2009. Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. J Physiol 587:3741-3750.
280. YILMAZ, M.I., M. SAGLAM, J.J. CARRERO, A.R. QURESHI, K. CAGLAR, T. EYILETEN, A. SONMEZ, Y.OGUZ, I. ASLAN, A. VURAL, M. YENICESU, P. STENVINKEL, B. LINDHOLM, and J. AXELSSON. 2009. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant 23:241-248.
281. ROMACHO, T., V. AZCUTIA, M. VAZQUEZ-BELLA, N. MATESANZ, E. CERCAS, J. NEVADO, R. CARRARO, L. RODRIGUEZ-MANAS, C.F. SANCHEZ-FERRER, and C. PEIRO. 2009. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 52:2455-2463.
282. AUST, G., O. RICHTER, S. ROHM, C. KERNER, J. HAUSS, N.KLOTING, K. RUSCHKE, P. KOVACS, B.S. YOUN, and M. BLUHER. 2009. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 204:262-266.
283. BOUCHER, J., B.MASRI,D.DAVIAUD, S.GESTA,C.GUIGNE,A.MAZZUCOTELLI, I.CASTAN-LAURELL, I. TACK, B. KNIBIEHLER, C. CARPENE, Y. AUDIGIER, J.S. SAULNIER-BLACHE, and P. VALET. 2005. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 146:1764-1771.
284. MALYSZKO, J., J.S. MALYSZKO, K. PAWLAK, S. WOLCZYNSKI, and M. MYSLIWIEC. 2008. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc 40:3466-3469.
285. BOYLE, P.J. 2007. Diabetes mellitus and macrovascular disease: mechanisms and mediators.AmJ Med 120:S12-S17.
286. EYRIES, M., G. SIEGFRIED, M. CIUMAS, K.MONTAGNE, M. AGRAPART, F. LEBRIN, and F. SOUBRIER. 2008. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res 103:432-440.
287. KUNDUZOVA, O., N.ALET, N.DELESQUE-TOUCHARD, L.MILLET, I. CASTAN-LAURELL, C.MULLER, C. DRAY, P. SCHAEFFER, J.P. HERAULT, P. SAVI, F. BONO, and P. VALET. 2008. Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes. FASEB J 22: 4146-4153.
288. SHEIKH, A.Y., H.J. CHUN, A.J. GLASSFORD, R.K. KUNDU, I. KUTSCHKA, D. ARDIGO, S.L. HENDRY, R.A. WAGNER, M.M. CHEN, Z.A. ALI, P. YUE, D.T. HUYNH, A.J. CONNOLLY, M.P. PELLETIER, P.S. TSAO, R.C. ROBBINS, and T.QUERTERMOUS. 2008. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol 294:H88-H98.
289. JAPP, A.G., and D.E.NEWBY. 2008. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 75:1882-1892.
290. ROGOWSKI, O., A. STEINVIL, S. BERLINER, M. COHEN, N. SAAR, O. KLIUK BEN-BASSAT, and I. SHAPIRA. 2009. Elevated resting heart rate is associated with the metabolic syndrome. Cardiovasc Diabetol 8:55.
291. TAMARIZ, L., B. HASSAN, A. PALACIO, L. ARCEMENT, R. HORSWELL, and K. HEBERT. 2009. Metabolic syndrome increases mortality in heart failure. Clin Cardiol 32:327-331.
292. WANG, J., S.RUOTSALAINEN, L.MOILANEN, P. LEPISTO, M. LAAKSO, and J.KUUSISTO. 2007. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 28:857-864.
293. PATEL, J.V., I. TRACEY, E.A. HUGHES, and G.Y. LIP. 2009. Unraveling the paradoxical link between obesity and heart failure: the role of adipocytokines. Expert Rev Cardiovasc Ther 7:337-340.
294. SODERBERG, S., D.COLQUHOUN, A. KEECH, J. YALLOP, E.H. BARNES, C. POLLICINO, J.SIMES, A.M. TONKIN, P. NESTEL, and LIPID Study Investigators. 2009. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. Int J Obes (Lond) 33:123-130.
295. ATKINSON, L.L., M.A. FISCHER, and G. D. LOPASCHUK. 2002. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylasemalonyl- CoA axis. J Biol Chem 277:29424-29430.
296. HINTZ, K.K., N.S. ABERLE, and J. REN. 2003. Insulin resistance induces hyperleptinemia, cardiac contractile dysfunction but not cardiac leptin resistance in ventricular myocytes. Int J Obes Relat Metab Disord 27:1196-1203.
297. ABE, Y., K. ONO, T. KAWAMURA, H. WADA, T. KITA, A. SHIMATSU, and K. HASEGAWA. 2007. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol 292:H2387-H2396.
298. SCHULZE, P.C., J.KRATZSCH, A. LINKE, N.SCHOENE, V. ADAMS, S. GIELEN, S.ERBS, S.MOEBIUS-WINKLER, and G. SCHULER. 2003. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 5:33-40.
299. DONG, F., and J. REN. 2007. Fitness or fatness-the debate continues for the role of leptin in obesityassociated heart dysfunction. Curr Diabetes Rev 3:159-164.
300. KARMAZYN, M., D.M. PURDHAM, V. RAJAPUROHITAM, and A. ZEIDAN. 2007. Leptin as a cardiac hypertrophic factor: a potential target for therapeutics. Trends Cardiovasc Med 17:206-211.
301. PINEIRO, R., M.J. IGLESIAS, R. GALLEGO, K. RAGHAY, S. EIRAS, J. RUBIO, C. DIEGUEZ, O. GUALILLO, J.R. GONZALEZ-JUANATEY, and F. LAGO. 2005. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 579:5163-5169.
302. SKURK, C., F. WITTCHEN, L. SUCKAU, H. WITT, M. NOUTSIAS, H. FECHNER, H.P. SCHULTHEISS, and W. POLLER. 2008. Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J 29:1168-1180.
303. ANTONIADES, C., A.S. ANTONOPOULOS, D. TOUSOULIS, and C. STEFANADIS. 2009. Adiponectin: from obesity to cardiovascular disease. Obes Rev 10:269-279.
304. TSUTAMOTO, T., T. TANAKA, H. SAKAI, C. ISHIKAWA, M. FUJII, T. YAMAMOTO, and M. HORIE. 2007. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 28:1723-1730.
305. AYERDEN EBINC, F., H. EBINC, U.DERICI, A.ARAL, C. AYBAY, G. TACOY, E. KOC, R. MUTLUAY, K.ALTOK REIS, Y. ERTEN, T. ARINSOY, and S. SINDEL. 2009. The relationship between adiponectin levels and proinflammatory cytokines and left ventricular mass in dialysis patients. J Nephrol 22:216-223.
306. EBINC, H., F.A. EBINC, Z.N. OZKURT, M.T. DOGRU, M. TULMAC, M. YILMAZ, and O. CAGLAYAN. 2008. Impact of adiponectin on left ventricular mass index in non-complicated obese subjects. Endocr J 55:523-528.
307. TSUKAMOTO, O., M. FUJITA, M. KATO, S. YAMAZAKI, Y. ASANO, A. OGAI, H. OKAZAKI, M. ASAI, Y. NAGAMACHI, N. MAEDA, Y. SHINTANI, T. MINAMINO, M. ASAKURA, I. KISHIMOTO, T. FUNAHASHI, H. TOMOIKE, and M. KITAKAZE. 2009. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 53:2070-2077.
308. WANG, Y., L. TAO, Y. YUAN, W.B. LAU, R. LI, B.L. LOPEZ, T.A. CHRISTOPHER, R. TIAN, and X.L. MA. 2009. Cardioprotective effect of adiponectin is partially mediated by its AMPK-independent antinitrative action. Am J Physiol Endocrinol Metab 297:E384-E391.
309. GONON, A.T., U.WIDEGREN, A.BULHAK, F. SALEHZADEH, J. PERSSON, P.O. SJOQUIST, and J. PERNOW. 2008. Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide. Cardiovasc Res 78:116-122.
310. WANG, Y., E. GAO, L. TAO,W.B. LAU, Y. YUAN, B.J.GOLDSTEIN, B.L. LOPEZ, T.A. CHRISTOPHER, R. TIAN, W. KOCH, and X.L. MA. 2009. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation 119:835-844.
311. NATARAJAN, R., F.N. SALLOUM, B.J. FISHER, R.C. KUKREJA, and A.A. FOWLER 3RD. 2008. HYPOXIA INDUCIBLE FACTOR-1 UPREGULATES ADIPONECTIN IN DIABETIC MOUSE HEARTS AND ATTENUATES POST-ISCHEMIC INJURY. J CARDIOVASC PHARMACOL 51:178-187.
312. NISHIMURA, M., Y. IZUMIYA, A.HIGUCHI, R. SHIBATA, J.QIU, C. KUDO, H.K. SHIN, M.A.MOSKOWITZ, and N. OUCHI. 2008. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 117:216-223.
313. BUTLER, J., A. KALOGEROPOULOS, V. GEORGIOPOULOU, N. DE REKENEIRE, N. RODONDI, A.L. SMITH, U. HOFFMANN, A.KANAYA, A.B. NEWMAN, S.B. KRITCHEVSKY, R.S. VASAN, P.W.WILSON, T.B. HARRIS, and Health ABC Study. 2009. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol 29:1144-1149.
314. FRANKEL, D.S., R.S.VASAN, R.B.D'AGOSTINO, E.J.BENJAMIN, D.LEVY, T.J.WANG, and J.B.MEIGS. 2009. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 53:754-762.
315. CHU, S., W. DING, K. LI, Y. PANG, and C. TANG. 2008. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 72:1249-1253.
316. WANG, B.W., H.F. HUNG, H. CHANG, P.KUAN, and K.G. SHYU. 2007. Mechanical stretch enhances the expression of resistin gene in cultured cardiomyocytes via tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol 293:H2305-H2312.
317. GAO, J., C. CHANG CHUA, Z. CHEN, H. WANG, X. XU, R.C. HAMDY, J.R. MCMULLEN, T. SHIOI, S. IZUMO, and B.H. CHUA. 2007. Resistin, an adipocytokine, offers protection against acute myocardial infarction. J Mol Cell Cardiol 43:601-609.
318. SIMPKIN, J.C., D.M. YELLON, S.M. DAVIDSON, S.Y. LIM, A.M.WYNNE, and C.C. SMITH. 2007. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol 102:518-528.
319. LIM, S.Y., S.M. DAVIDSON, A.J. PARAMANATHAN, C.C. SMITH, D.M. YELLON, and D.J. HAUSENLOY. 2008. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 12: 1395-1403.
320. LAMOUNIER-ZEPTER, V., C. LOOK, J. ALVAREZ, T. CHRIST, U. RAVENS, W.H. SCHUNCK, M. EHRHARTBORNSTEIN, S.R. BORNSTEIN, and I. MORANO. 2009. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res 105:326-334.
321. WANNAMETHEE, S.G. 2009. Interventions to increase adiponectin may be associated with increased coronary heart disease in older adults. Future Cardiol 5:19-22.
322. GERMAN, A.J., M. HERVERA, L. HUNTER, S.L. HOLDEN, P.J.MORRIS, V. BIOURGE, and P. TRAYHURN. 2009. Improvement in insulin resistance and reduction in plasma inflammatory adipokines after weight loss in obese dogs. Domest Anim Endocrinol 37:214-226.
323. MONZILLO, L.U., O. HAMDY, E.S. HORTON, S. LEDBURY, C. MULLOOLY, C. JAREMA, S. PORTER, K. OVALLE, A. MOUSSA, and C.S. MANTZOROS. 2003. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 11:1048-1054.
324. VARADY, K.A., L. TUSSING, S. BHUTANI, and C.L. BRAUNSCHWEIG. 2009. Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism 58:1096-1101.
325. BALLANTYNE, G.H., A. GUMBS, and I.M. MODLIN. 2005. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg 15:692-699.
326. GUMBS, A.A., I.M. MODLIN, and G.H. BALLANTYNE. 2005. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg 15:462-473.
327. BUSETTO, L., F.BASSETTO,M. ZOCCHI, F. ZULIANI, M.L.NOLLI, S. PIGOZZO, A. COIN,M.MAZZA, G. SERGI, F.MAZZOLENI, and G. ENZI. 2008. The effects of the surgical removal of subcutaneous adipose tissue on energy expenditure and adipocytokine concentrations in obese women. Nutr Metab Cardiovasc Dis 18:112-120.
328. ESPOSITO, K., M. CIOTOLA, D. CARLEO, B. SCHISANO, F. SACCOMANNO, F.C. SASSO, D. COZZOLINO, R.ASSALONI, D.MERANTE, A. CERIELLO, and D.GIUGLIANO. 2006. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29:1071-1076.
329. BEHRE, C.J., A. GUMMESSON, M. JERNAS, T.C. LYSTIG, B. FAGERBERG, B. CARLSSON, and L.M. CARLSSON. 2007. Dissociation between adipose tissue expression and serum levels of adiponectin during and after diet-induced weight loss in obese subjects with and without the metabolic syndrome. Metabolism 56:1022-1028.
330. NG, T.W., G.F.WATTS, P.H.BARRETT, K.A.RYE, and D.C.CHAN. 2007. Effect of weight loss onLDLand HDLkinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein- 4 and adiponectin levels. Diabetes Care 30:2945-2950.
331. ESPOSITO, K., A. PONTILLO, C. DI PALO, G.GIUGLIANO, M. MASELLA, R. MARFELLA, and D. GIUGLIANO. 2003. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289:1799-1804.
332. PARK, T.G., H.R. HONG, J. LEE, and H.S. KANG. 2007. Lifestyle plus exercise intervention improves metabolic syndrome markers without change in adiponectin in obese girls. Ann Nutr Metab 51:197-203.
333. CHOI, K.M., T.N.KIM, H.J.YOO, K.W. LEE, G.J.CHO, T.G.HWANG, S.H.BAIK, D.S.CHOI, and S.M.KIM. 2009. Effect of exercise training on A-FABP, lipocalin-2 and RBP4 levels in obese women. Clin Endocrinol (Oxf) 70:569-574.
334. YAMAUCHI, T., and T. KADOWAKI. 2008. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 32 (Suppl 7): S13-S18.
335. STERN, N., E. OSHER, and Y. GREENMAN. 2007. Hypoadiponectinemia as a marker of adipocyte dysfunction-part II: the functional significance of low adiponectin secretion. J Cardiometab Syndr 2:288-294.
336. PASARICA, M., Y.D. TCHOUKALOVA, L.K. HEILBRONN, X. FANG, J.B. ALBU, D.E. KELLEY, S.R. SMITH, E. RAVUSSIN, and The Look AHEAD Adipose Research Group. 2009. Differential effect of weight loss on adipocyte size subfractions in patients with type 2 diabetes. Obesity (Silver Spring) 17:1976-1978.
337. REINEHR, T., M. KLEBER, and A.M. TOSCHKE. 2009. Lifestyle intervention in obese children is associated with a decrease of the metabolic syndrome prevalence. Atherosclerosis 207:174-180.
338. YASSINE, H.N., C.M. MARCHETTI, R.K. KRISHNAN, T.R. VROBEL, F. GONZALEZ, and J.P. KIRWAN. 2009. Effects of exercise and caloric restriction on insulin resistance and cardiometabolic risk factors in older obese adults-a randomized clinical trial. J Gerontol A Biol Sci Med Sci 64:90-95.
339. BO, S., G. CICCONE, S. GUIDI, R. GAMBINO, M. DURAZZO, L. GENTILE, M. CASSADER, P. CAVALLO-PERIN, and G. PAGANO. 2008. Diet or exercise: what is more effective in preventing or reducing metabolic alterations? Eur J Endocrinol 159:685-691.
340. BRADLEY, U., M. SPENCE, C.H. COURTNEY, M.C.MCKINLEY, C.N. ENNIS, D.R.MCCANCE, J. MCENENY, P. M. BELL, I.S.YOUNG, and S.J.HUNTER. 2009. Low-fat versus low-carbohydrate weight reduction diets: effects on weight loss, insulin resistance and cardiovascular risk: a randomised control trial. Diabetes 58:2741-2748.
341. DECORDE, K., P.L. TEISSEDRE, T.SUTRA, E.VENTURA, J.P.CRISTOL, and J.M.ROUANET. 2009. Chardonnay grape seed procyanidin extract supplementation prevents high-fat diet-induced obesity in hamsters by improving adipokine imbalance and oxidative stress markers. Mol Nutr Food Res 53:659-666.
342. LAGOUGE, M., C. ARGMANN, Z. GERHART-HINES, H. MEZIANE, C. LERIN, F. DAUSSIN, N. MESSADEQ, J.MILNE, P. LAMBERT, P. ELLIOTT, B. GENY,M. LAAKSO, P. PUIGSERVER, and J.AUWERX. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109-1122.
343. RIVERA, L., R. MORON, A. ZARZUELO, and M. GALISTEO. 2009. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 77:1053-1063.
344. NISHIZAWA, N., T. TOGAWA, K.O. PARK, D. SATO, Y. MIYAKOSHI, K. INAGAKI, N. OHMORI, Y. ITO, and T.NAGASAWA. 2009. Dietary Japanese millet protein ameliorates plasma levels of adiponectin, glucose, and lipids in type 2 diabetic mice. Biosci Biotechnol Biochem 73:351-360.
345. JOBGEN, W., C.J. MEININGER, S.C. JOBGEN, P. LI, M.J. LEE, S.B. SMITH, T.E. SPENCER, S.K. FRIED, and G.WU. 2009. Dietary L-arginine supplementation reduces white fat gain and enhances skeletal muscle and brown fat masses in diet-induced obese rats. J Nutr 139:230-237.
346. SHIMADA, K., T. KAWARABAYASHI, A. TANAKA, D. FUKUDA, Y. NAKAMURA, M. YOSHIYAMA, K. TAKEUCHI, T. SAWAKI, K. HOSODA, and J. YOSHIKAWA. 2004. Oolong tea increases plasma adiponectin levels and low-density lipoprotein particle size in patients with coronary artery disease. Diabetes Res Clin Pract 65:227-234.
347. FLACHS, P., V. MOHAMED-ALI, O. HORAKOVA, M. ROSSMEISL, M.J. HOSSEINZADEH-ATTAR, M. HENSLER, J.RUZICKOVA, and J.KOPECKY. 2006. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 49:394-397.
348. SONG, M.Y., N. LV, E.K. KIM, K.S.KWON, Y.B. YOO, J.H. KIM, S.W. LEE, J.H. SONG, J.H. LEE, S.K. LEE, B.C. SHIN, D.G. RYU, B.H. PARK, and K.B. KWON. 2009. Antiobesity activity of aqueous extracts of Rhizoma Dioscoreae Tokoronis on high-fat diet-induced obesity in mice. J Med Food 12:304-309.
349. NEYRINCK, A.M., L.B. BINDELS, F. DE BACKER, B.D. PACHIKIAN, P.D. CANI, and N.M. DELZENNE. 2009. Dietary supplementation with chitosan derived from mushrooms changes adipocytokine profile in diet-induced obese mice, a phenomenon linked to its lipid-lowering action. Int Immunopharmacol 9:767-773.
350. OISHI, Y., and N. DOHMOTO. 2009. Alaska pollack protein prevents the accumulation of visceral fat in rats fed a high fat diet. J Nutr Sci Vitaminol (Tokyo) 55:156-161.
351. PAUSOVA, Z. 2006. From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr Opin Nephrol Hypertens 15:173-178.
352. DECLERCQ, V., C. TAYLOR, and P. ZAHRADKA. 2008. Adipose tissue: the link between obesity and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets 8:228-237.
353. PILVI, T.K., S. HARALA, R. KORPELA, and E.M. MERVAALA. 2009. Effects of high-calcium diets with different whey proteins on weight loss and weight regain in high-fat-fed C57BL/6J mice. Br J Nutr 102:337-341.
354. WOO, M.N., S.H. BOK, M.K. LEE, H.J. KIM, S.M. JEON, G.M. DO, S.K. SHIN, T.Y. HA, and M.S. CHOI. 2008. Anti-obesity and hypolipidemic effects of a proprietary herb and fiber combination (S&SPWH) in rats fed high-fat diets. J Med Food 11:169-178.
355. LEE, J.S., M.K. LEE, T.Y.HA, S.H. BOK, H.M. PARK, K.S. JEONG, M.N. WOO, G.M. DO, J.Y. YEO, and M.S. CHOI. 2006. Supplementation of whole persimmon leaf improves lipid profiles and suppresses body weight gain in rats fed high-fat diet. Food Chem Toxicol 44:1875-1883.
356. NOTO, A., P. ZAHRADKA, N. YURKOVA, X. XIE, E. NITSCHMANN, M. OGBORN, and C.G. TAYLOR. 2006. Conjugated linoleic acid reduces hepatic steatosis, improves liver function, and favorably modifies lipid metabolism in obese insulin-resistant rats. Lipids 41:179-188.
357. LARSEN, T.M., S. TOUBRO, O. GUDMUNDSEN, and A. ASTRUP. 2006. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain. Am J Clin Nutr 83:606-612.
358. WHIGHAM, L.D., A.C. WATRAS, and D.A. SCHOELLER. 2007. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J Clin Nutr 85:1203-1211.
359. SILVEIRA, M.B., R. CARRARO, S. MONEREO, and J. Tebar. 2007. Conjugated linoleic acid (CLA) and obesity. Public Health Nutr 10:1181-1186.
360. GAULLIER, J.M., J. HALSE, K.HOYE, K.KRISTIANSEN, H. FAGERTUN, H.VIK, and O. GUDMUNDSEN. 2004. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin Nutr 79:1118-1125.
361. NOTO, A., P. ZAHRADKA, N.R. RYZ, N. YURKOVA, X. XIE, and C.G. TAYLOR. 2007. Dietary conjugated linoleic acid preserves pancreatic function and reduces inflammatory markers in obese, insulinresistant rats. Metabolism 56:142-151.
362. DRURY, B., L.J. WARFORD-WOOLGAR, D.J. HERCHAK, N. BANKOVIC-CALIC, G. CROW, C.G. TAYLOR, P. ZAHRADKA, M.R. OGBORN, and H.M. AUKEMA. 2009. Dietary trans-10, cis-12 conjugated linoleic acid reduces early glomerular enlargement and elevated renal cyclooxygenase-2 levels in young obese fa/fa zucker rats. J Nutr 139:285-290.
363. NOTO, A., P. ZAHRADKA, N. YURKOVA, X. XIE, H. TRUONG, E. NITSCHMANN, M.R. OGBORN, and C.G. TAYLOR. 2007. Dietary conjugated linoleic acid decreases adipocyte size and favorably modifies adipokine status and insulin sensitivity in obese, insulin-resistant rats. Metabolism 56:1601-1611.
364. NAGAO, K., N. INOUE, Y.M. WANG, and T. YANAGITA. 2003. Conjugated linoleic acid enhances plasma adiponectin level and alleviates hyperinsulinemia and hypertension in Zucker diabetic fatty (fa/fa) rats. Biochem Biophys Res Commun 310:562-566.
365. LASA, A., I. CHURRUCA, E. SIMON, A. FERNANDEZ-QUINTELA, V.M. RODRIGUEZ, and M.P. PORTILLO. 2008. Trans-10, cis-12-conjugated linoleic acid does not increase body fat loss induced by energy restriction. Br J Nutr 100:1245-1250.
366. SYVERTSEN, C., J. HALSE, H.O. HOIVIK, J.M. GAULLIER, M. NURMINIEMI, K.KRISTIANSEN, A. EINERHAND, M. O'SHEA, and O. GUDMUNDSEN. 2007. The effect of 6 months supplementation with conjugated linoleic acid on insulin resistance in overweight and obese. Int J Obes (Lond) 31:1148-1154.
367. SNEDDON, A.A., F. TSOFLIOU, C.L. FYFE, I. MATHESON, D.M. JACKSON, G. HORGAN, M.S.WINZELL, K.W. WAHLE, B. AHREN, and L.M. WILLIAMS. 2008. Effect of a conjugated linoleic acid and omega-3 fatty acid mixture on body composition and adiponectin. Obesity (Silver Spring) 16:1019-1024.
368. RAYALAM, S., M.A. DELLA-FERA, and C.A. BAILE. 2008. Phytochemicals and regulation of the adipocyte life cycle. J Nutr Biochem 19:717-726.
369. MENDES, V., R. MONTEIRO, D. PESTANA, D. TEIXEIRA, C. CALHAU, and I. AZEVEDO. 2008. Xanthohumol influences preadipocyte differentiation: implication of antiproliferative and apoptotic effects. J Agric Food Chem 56:11631-11637.
370. PARK, H.J., J.Y. YANG, S. AMBATI, M.A. DELLA-FERA, D.B. HAUSMAN, S. RAYALAM, and C.A. BAILE. 2008. Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes. J Med Food 11:773-783.
371. MOON, H.S., C.S. CHUNG, H.G. LEE, T.G. KIM, Y.J. CHOI, and C.S. CHO. 2007. Inhibitory effect of (-)-epigallocatechin-3-gallate on lipid accumulation of 3T3-L1 cells. Obesity (Silver Spring) 15:2571-2582.
372. YANG, J.Y., M.A.DELLA-FERA, and C.A. BAILE. 2008. Guggulsterone inhibits adipocyte differentiation and induces apoptosis in 3T3-L1 cells. Obesity (Silver Spring) 16:16-22.
373. SZKUDELSKA, K., L. NOGOWSKI, and T. SZKUDELSKI. 2009. The inhibitory effect of resveratrol on leptin secretion from rat adipocytes. Eur J Clin Invest 39:899-905.
374. VUONG, T., A. BENHADDOU-ANDALOUSSI, A. BRAULT, D. HARBILAS, L.C. MARTINEAU, D. VALLERAND, C. RAMASSAMY, C. MATAR, and P.S. HADDAD. 2009. Antiobesity and antidiabetic effects of biotransformed blueberry juice in KKA(y) mice. Int J Obes (Lond) 33:1166-1173.
375. VAN DER SPUY,W.J., and E. PRETORIUS. 2009. Is the use of resveratrol in the treatment and prevention of obesity premature? Nutr Res Rev 1-7.
376. BUETTNER, C., E.D.MUSE, A.CHENG, L. CHEN, T.SCHERER, A.POCAI, K.SU, B. CHENG, X.LI, J.HARVEYWHITE, G.J. SCHWARTZ, G.KUNOS, L. ROSSETTI, and C. BUETTNER. 2008. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 14:667-675.
377. SHIMABUKURO, M., K.KOYAMA, G.CHEN, M.Y.WANG, F. TRIEU, Y. LEE, C.B.NEWGARD, and R.H.UNGER. 1997. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci USA 94:4637-4641.
378. WANG, M.Y., Y. LEE, and R.H. UNGER. 1999. Novel form of lipolysis induced by leptin. J Biol Chem 274:17541-17544.
379. CHONG, A.Y., B.C. LUPSA, E.K. COCHRAN, and P. GORDEN. 2010. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53:27-35.
380. CHEN, J.X., and A. STINNETT. 2008. Critical role of the NADPH oxidase subunit p47phox on vascular TLR expression and neointimal lesion formation in high-fat diet-induced obesity. Lab Invest 88:1316-1328.
381. KNIGHT,W.D., R. SETH, J.BORON, and J.M. OVERTON. 2009. Short-term physiological hyperleptinemia decreases arterial blood pressure. Regul Pept 154:60-68.
382. TREVASKIS, J.L., C. LEI, J.E. KODA, C. WEYER, D.G. PARKES, and J.D. ROTH. 2010. Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. Obesity (Silver Spring) 18:21-26.
383. SATOH, H., M.T. NGUYEN, M. TRUJILLO, T. IMAMURA, I. USUI, P.E. SCHERER, and J.M. OLEFSKY. 2005. Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes 54:1304-1313.
384. LYZOGUBOV, V.V., R.G. TYTARENKO, S. THOTAKURA, T. VISWANATHAN, N.S. BORA, and P.S. BORA. 2009. Inhibition of new vessel growth in mouse model of laser-induced choroidal neovascularization by adiponectin peptide II. Cell Biol Int 33:765-771.
385. RAJALA,M.W., S.OBICI, P.E. SCHERER, and L.ROSSETTI. 2003. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111:225-230.
386. XU, A., S. YIN, L. WONG, K.W. CHAN, and K.S. LAM. 2004. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 145:487-494.
387. YAMAUCHI, T., J.KAMON, H.WAKI, Y. TERAUCHI, N.KUBOTA, K.HARA, Y.MORI, T. IDE, K.MURAKAMI, N. TSUBOYAMA-KASAOKA, O.EZAKI, Y.AKANUMA, O.GAVRILOVA, C. VINSON, M.L. REITMAN, H.KAGECHIKA, K. SHUDO, M. YODA, Y. NAKANO, K. TOBE, R. NAGAI, S. KIMURA, M. TOMITA, P. FROGUEL, and T. KADOWAKI. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946.
388. KAPICA, M., I. PUZIO, I.KATO, A.KUWAHARA, and R. ZABIELSKI. 2008. Role of feed-regulating peptides on pancreatic exocrine secretion. J Physiol Pharmacol 59 (Suppl 2): 145-159.
389. DANIELSSON, T., L. FREDRIKSSON, L. JANSSON, and J. HENRIKSNAS. 2009. Resistin increases islet blood flow and decreases subcutaneous adipose tissue blood flow in anaesthetized rats. Acta Physiol (Oxf) 195:283-288.
390. YU, X., B.H. PARK, M.Y. WANG, Z.V. WANG, and R.H. UNGER. 2008. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci USA 105:14070-14075.
391. QIAO, L., C. ZOU, D.R. VAN DER WESTHUYZEN, and J. SHAO. 2008. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes 57:1824-1833.
392. FILIPPATOS, T.D., D.N.KIORTSIS, E.N. LIBEROPOULOS,M.GEORGOULA, D.P.MIKHAILIDIS, and M.S. ELISAF. 2005. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 21:1997-2006.
393. BROOK, R.D., R.L. BARD, L. GLAZEWSKI, C. KEHRER, P.F. BODARY, D.L. EITZMAN, and S. RAJAGOPALAN. 2004. Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am J Cardiol 93:1012-1016.
394. SWARBRICK, M.M., and P.J.HAVEL. 2008. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 6:87-102.
395. GUREVICH-PANIGRAHI, T., S. PANIGRAHI, E. WIECHEC, and M. LOS. 2009. Obesity: pathophysiology and clinical management. Curr Med Chem 16:506-521.
396. PETERSON, S.J., W.H. FRISHMAN, and N.G. ABRAHAM. 2009. Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiol Rev 17:99-111.
397. RIKITAKE, Y., and K. HIRATA. 2009. Inhibition of RhoA or Rac1? Mechanism of cholesterolindependent beneficial effects of statins. Circ J 73:231-232.
398. TOMIYAMA, K., E. NISHIO, and Y. WATANABE. 1999. Both wortmannin and simvastatin inhibit the adipogenesis in 3T3-L1 cells during the late phase of differentiation. Jpn J Pharmacol 80:375-378.
399. ANDO, H., K. SUGIMOTO, H. YANAGIHARA, S. TSURUOKA, T. SAITO, T. TAKAMURA, S. KANEKO, and A. FUJIMURA. 2008. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatorymarkers in hypercholesterolaemic patients. ClinExpPharmacolPhysiol 35:1012-1017.
400. MAEDA, T., and N.HORIUCHI. 2009. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation. J Biochem 145:771-781.
401. ARAKI, K., T. MASAKI, I. KATSURAGI, T. KAKUMA, and H. YOSHIMATSU. 2008. Effects of pravastatin on obesity, diabetes, and adiponectin in diet-induced obese mice. Obesity (Silver Spring) 16:2068-2073.
402. BOAZ, M., L. LISY, G. ZANDMAN-GODDARD, and J. WAINSTEIN. 2009. The effect of anti-inflammatory (aspirin and/or statin) therapy on body weight in Type 2 diabetic individuals: EAT, a retrospective study. Diabet Med 26:708-713.
403. SUGIYAMA, S., H. FUKUSHIMA, K. KUGIYAMA, H. MARUYOSHI, S. KOJIMA, T. FUNAHASHI, T. SAKAMOTO, Y. HORIBATA, K. WATANABE, H. KOGA, K. SUGAMURA, F. OTSUKA, I. SHIMOMURA, and H. OGAWA. 2007. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 194:e43-e51.
404. NOMURA, S., N. INAMI,A. SHOUZU, S.OMOTO,Y.KIMURA,N.TAKAHASHI,A.TANAKA, F.URASE,Y.MAEDA, H. OHTANI, and T. IWASAKA. 2009. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 20:16-22.
405. HYOGO, H., S. TAZUMA, K. ARIHIRO, K. IWAMOTO, Y. NABESHIMA, M. INOUE, T. ISHITOBI, M. NONAKA, and K. CHAYAMA. 2008. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 57:1711-1718.
406. VAN HOEK, M., A. VAN TOL, L.C. VAN VARK-VAN DER ZEE, H. JANSEN, J.J. KASTELEIN, E.J. SIJBRANDS, and G.M. DALLINGA-THIE. 2009. Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes. Curr Med Res Opin 25:93-101.
407. TAKEBAYASHI, K., M. SUETSUGU, S. MATSUMOTO, Y. ASO, and T. INUKAI. 2009. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J 102:361-368.
408. KOH, K.K., M.J. QUON, S.H. HAN, Y. LEE, S.J. KIM, J.B. PARK, and E.K. SHIN. 2009. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 204:483-490.
409. VAN RAALTE, D.H., M. LI, P.H. PRITCHARD, and K.M. WASAN. 2004. Peroxisome proliferatoractivated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res 21:1531-1538.
410. JEONG, S., M. HAN, H. LEE, M.KIM, J. KIM, C.J. NICOL, B.H. KIM, J.H. CHOI, K.H. NAM, G.T. OH, and M. YOON. 2004. Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism 53:1284-1289.
411. JEONG, S., and M. YOON. 2009. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice. Exp Mol Med 41:397-405.
412. KOH, K.K., S.H.HAN, M.J.QUON, J. YEALAHN, and E.K. SHIN. 2005. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28:1419-1424.
413. VASUDEVAN, A.R., and A.BALASUBRAMANYAM. 2004. Thiazolidinediones: a reviewof their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 6:850-863.
414. PEREIRA, R.I., J.W. LEITNER, C. ERICKSON, and B. DRAZNIN. 2008. Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 30- kinase. Life Sci 83:638-643.
415. MINEO, H., C. ODA, H. CHIJI, T. KAWADA, K. SHIMIZU, and T. TAIRA. 2007. Thiazolidinediones exhibit different effects on preadipocytes isolated from rat mesenteric fat tissue and cell line 3T3-L1 cells derived from mice. Cell Biol Int 31:703-710.
416. GHANIM, H., S. DHINDSA, A.ALJADA, A. CHAUDHURI, P. VISWANATHAN, and P.DANDONA. 2006. Low-dose rosiglitazone exertsanantiinflammatoryeffectwithanincrease inadiponectinindependently offreefatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab 91:3553-3558.
417. SZAPARY, P.O., L.T. BLOEDON, F.F. SAMAHA, D.DUFFY, M.L.WOLFE, D.SOFFER, M.P. REILLY, J.CHITTAMS, and D.J. RADER. 2006. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 26:182-188.
418. SAMAHA, F.F., P.O. SZAPARY, N. IQBAL, M.M. WILLIAMS, L.T. BLOEDON, A. KOCHAR, M.L. WOLFE, and D.J. RADER. 2006. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26:624-630.
419. BAHIA, L., L.G. AGUIAR, N.VILLELA, D. BOTTINO, A.F. GODOY-MATOS, B. GELONEZE,M. TAMBASCIA, and E. BOUSKELA. 2007. Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. Atherosclerosis 195:138-146.
420. WAY, J.M., C.Z. GORGUN, Q. TONG, K.T. UYSAL, K.K. BROWN, W.W. HARRINGTON, W.R. OLIVER, JR., T.M. WILLSON, S.A. KLIEWER, AND G.S. HOTAMISLIGIL. 2001. ADIPOSE TISSUE RESISTIN EXPRESSION IS SEVERELY SUPPRESSED IN OBESITY AND STIMULATED BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AGONISTS. J BIOL CHEM 276:25651-25653.
421. MOORE, G.B., H. CHAPMAN, J.C. HOLDER, C.A. LISTER, V. PIERCY, S.A. SMITH, and J.C. CLAPHAM. 2001. Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun 286:735-741.
422. HARTMAN, H.B., X. HU, K.X. TYLER, C.K. DALAL, and M.A. LAZAR. 2002. Mechanisms regulating adipocyte expression of resistin. J Biol Chem 277:19754-19761.
423. MAEDA, N., M. TAKAHASHI, T. FUNAHASHI, S. KIHARA, H. NISHIZAWA, K. KISHIDA, H. NAGARETANI, M. MATSUDA, R. KOMURO, N. OUCHI, H. KURIYAMA, K. HOTTA, T. NAKAMURA, I. SHIMOMURA, and Y. MATSUZAWA. 2001. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099.
424. YU, J.G., S. JAVORSCHI, A.L. HEVENER, Y.T. KRUSZYNSKA, R.A. NORMAN, M. SINHA, and J.M. OLEFSKY. 2002. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968-2974.
425. TONELLI, J., W. LI, P. KISHORE, U.B. PAJVANI, E. KWON, C. WEAVER, P.E. SCHERER, and M. HAWKINS. 2004. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53:1621-1629.
426. KRZYZANOWSKA, K., F. MITTERMAYER, W. KRUGLUGER, M. RODEN, G. SCHERNTHANER, and M. WOLZT. 2007. Adiponectin concentrations increase during acute FFA elevation in humans treated with rosiglitazone. Horm Metab Res 39:769-772.
427. MITTERMAYER, F., G. SCHALLER, J. PLEINER, K. KRZYZANOWSKA, S. KAPIOTIS, M.RODEN, and M.WOLZT. 2007. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J Clin Endocrinol Metab 92:2574-2580.
428. AITHAL, G.P., J.A. THOMAS, P.V. KAYE, A. LAWSON, S.D. RYDER, I. SPENDLOVE, A.S. AUSTIN, J.G. FREEMAN, L. MORGAN, and J. WEBBER. 2008. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135:1176-1184.
429. BELFORT, R., S.A. HARRISON, K. BROWN, C. DARLAND, J. FINCH, J. HARDIES, B. BALAS, A.GASTALDELLI, F. TIO, J. PULCINI, R. BERRIA, J.Z. MA, S. DWIVEDI, R. HAVRANEK, C. FINCKE, R. DEFRONZO, G.A. BANNAYAN, S.SCHENKER, and K. CUSI. 2006.Aplacebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297-2307.
430. RAN, J., T. HIRANO, T. FUKUI, K. SAITO, H. KAGEYAMA, K. OKADA, and M. ADACHI. 2006. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 55:478-488.
431. WEISINGER, R.S., T.K. STANLEY, D.P. BEGG, H.S.WEISINGER, K.J. SPARK, and M. JOIS. 2009. Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol Behav 98:192-197.
432. KUDO, H., Y. YATA, T. TAKAHARA, K. KAWAI, Y. NAKAYAMA, M. KANAYAMA, T. OYA, S. MORITA, M. SASAHARA, D.A. MANN, and T. SUGIYAMA. 2009. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int 29:988-996.
433. KOH, K.K., M.J. QUON, S.H. HAN, W.J. CHUNG, J.Y. AHN, Y.H. SEO, M.H. KANG, T.H. AHN, I.S. CHOI, and E.K. SHIN. 2004. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110:3687-3692.
434. FURUHASHI, M., N. URA, K. HIGASHIURA, H.MURAKAMI, M. TANAKA, N.MONIWA, D. YOSHIDA, and K. SHIMAMOTO. 2003. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76-81.
435. NIELSEN, S., A.S. LIHN, T. OSTERGAARD, C.E. MOGENSEN, and O. SCHMITZ. 2004. Increased plasma adiponectin in losartan-treated type 1 diabetic patients. A mediator of improved insulin sensitivity? Horm Metab Res 36:194-196.
436. YILMAZ, M.I., A. SONMEZ,K.CAGLAR, T. CELIK,M.YENICESU, T.EYILETEN, C.ACIKEL,Y.OGUZ, I.YAVUZ, and A. VURAL. 2007. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 12:147-153.
437. WEIR, M.R. 2007. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 29:1803-1824.
438. MAKITA, S., A. ABIKO, Y. NAGANUMA, Y. MORIAI, and M. NAKAMURA. 2008. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism 57:1473-1478.
439. MORI, Y., Y. ITOH, and N. TAJIMA. 2007. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 24:146-153.
440. SUN, Y., K. XUN, C. WANG, H. ZHAO, H. BI, X. CHEN, and Y. WANG. 2009. Adiponectin, an unlocking adipocytokine. Cardiovasc Ther 27:59-75.
441. HUANG, S.S., T.C. WU, S.J. LIN, and J.W. CHEN. 2009. Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J 73:2282-2287.
442. PIECHA, G., M.ADAMCZAK, J. CHUDEK, and A.WIECEK. 2007. Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. Kidney Blood Press Res 30:187-194.
443. VIOLLET, B., R.MOUNIER, J. LECLERC, A.YAZIGI, M. FORETZ, and F. ANDREELLI. 2007. Targeting AMPactivated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 33:395-402.
444. FRUEHWALD-SCHULTES, B., K.M. OLTMANNS, B. TOSCHEK, S. SOPKE, W. KERN, J. BORN, H.L. FEHM, and A. PETERS. 2002. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism 51:531-536.
445. TOMAS, E., T.S. TSAO, A.K. SAHA, H.E. MURREY, C. ZHANG CC, S.I. ITANI, H.F. LODISH, and N.B. RUDERMAN. 2002. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309-16313.
446. FUJITA,H.,H.FUJISHIMA,T.MORII,J.KOSHIMURA,T.NARITA,M.KAKEI,andS.ITO.2002.Effectofmetformin on adipose tissue resistin expression in db/db mice. Biochem Biophys Res Commun 298:345-349.
447. SHENG, C.H., J. DI, Y. JIN, Y.C. ZHANG, M.WU, Y. SUN, and G.Z. ZHANG. 2008. Resistin is expressed in human hepatocytes and induces insulin resistance. Endocrine 33:135-143.
448. MATIAS, I., and V. DI MARZO. 2007. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18:27-37.
449. ENGELI, S., J.BOHNKE,M. FELDPAUSCH,K.GORZELNIAK, J. JANKE, S. BATKAI, P.PACHER, J.HARVEY-WHITE, F.C. LUFT, A.M. SHARMA, and J. JORDAN. 2005. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54:2838-2843.
450. WOODS, S.C. 2007. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. JAAPA Suppl Endocannabinoid: 7-10.
451. BERMUDEZ-SILVA, F.J., I. SANCHEZ-VERA, J. SUAREZ, A. SERRANO, E. FUENTES, P. JUAN-PICO, A. NADAL, and F.RODRIGUEZ DE FONSECA. 2007. Role of cannabinoidCB2receptors in glucose homeostasis in rats. Eur J Pharmacol 565:207-211.
452. DEVEAUX, V., T. CADOUDAL, Y. ICHIGOTANI, F. TEIXEIRA-CLERC, A. LOUVET, S. MANIN, J.T. NHIEU, M.P. BELOT, A. ZIMMER, P. EVEN, P.D. CANI, C. KNAUF, R. BURCELIN, A. BERTOLA, Y. LE MARCHANDBRUSTEL, P. GUAL, A. MALLAT, and S. LOTERSZTAJN. 2009. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 4:e5844.
453. GARY-BOBO, M., G. ELACHOURI, J.F. GALLAS, P. JANIAK, P. MARINI, C. RAVINET-TRILLOU, M. CHABBERT, N. CRUCCIOLI, C. PFERSDORFF, C. ROQUE, M. ARNONE, T. CROCI, P. SOUBRIE, F. OURY-DONAT, J.P. MAFFRAND, B. SCATTON, F. LACHERETZ, G. LE FUR, J.M. HERBERT, and M. BENSAID. 2007. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46:122-129.
454. DESPRES, J.P., A.GOLAY, L. SJOSTROM, and Rimonabant in Obesity-Lipids Study Group. 2005. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134.
455. BENSAID, M., M.GARY-BOBO, A. ESCLANGON, J.P.MAFFRAND, G.LE FUR, F.OURY-DONAT, and P. SOUBRIE. 2003. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-914.
456. DESPRES, J.P., R. ROSS, G. BOKA, N. ALMERAS, I. LEMIEUX, and ADAGIO-Lipids Investigators. 2009. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 29:416-423.
457. THORNTON-JONES, Z.D., G.A. KENNETT, K.R. BENWELL, D.F. REVELL, A. MISRA, D.M. SELLWOOD, S.P. VICKERS, and P.G. CLIFTON. 2006. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 84:353-359.
458. VAN GAAL, L., X. PI-SUNYER, J.P. DESPRES, C. MCCARTHY, and A. SCHEEN. 2008. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 (Suppl 2): S229-S240.
459. SCHEEN, A.J., N. FINER, P.HOLLANDER, M.D. JENSEN, L.F. VAN GAAL, and RIO-Diabetes Study Group. 2006. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368:1660-1672.
460. MALCHER-LOPES, R., S. DI, V.S. MARCHESELLI, F.J.WENG, C.T. STUART, N.G. BAZAN, and J.G. TASKER. 2006. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 26:6643-6650.
461. DI MARZO, V., A. LIGRESTI, and L. CRISTINO. 2009. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes (Lond) 33 (Suppl 2): S18-S24.
462. SEELY, K.A., M.S. LEVI, and P.L. PRATHER. 2009. The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists. J Pharmacol Exp Ther 330:31-39.
463. CEFALU, W.T., and K. WATSON. 2008. Intensive glycemic control and cardiovascular disease observations from the ACCORD study: now what can a clinician possibly think? Diabetes 57: 1163-1165.
464. LIJNEN, H.R., B. VAN HOEF, H.R. LU, and D.J. GALLACHER. 2008. Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. Thromb Haemost 100:338-342.
465. FAIN, J.N., L.R. BALLOU, and S.W. BAHOUTH. 2001. Obesity is induced in mice heterozygous for cyclooxygenase-2. Prostaglandins Other Lipid Mediat 65:199-209.
466. FAIN, J.N., C.W. LEFFLER, and S.W. BAHOUTH. 2000. Eicosanoids as endogenous regulators of leptin release and lipolysis by mouse adipose tissue in primary culture. J Lipid Res 41:1689-1694.
467. WEISBERG, S.P., D. HUNTER, R. HUBER, J. LEMIEUX, S. SLAYMAKER, K. VADDI, I. CHARO, R.L. LEIBEL, and A.W. FERRANTEJR. 2006. CCR2 MODULATES INFLAMMATORY AND METABOLIC EFFECTS OF HIGH-FAT FEEDING. J CLIN INVEST 116:115-124.
468. CHEN, A., S.MUMICK, C. ZHANG, J. LAMB, H. DAI, D.WEINGARTH, J. MUDGETT, H. CHEN, D.J.MACNEIL, M.L. REITMAN, and S. QIAN. 2005. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res 13:1311-1320.
469. HOLLUNG, K., C.P. RISE, C.A. DREVON, and J.E. RESELAND. 2004. Tissue-specific regulation of leptin expression and secretion by all-trans retinoic acid. J Cell Biochem 92:307-315.
470. FELIPE, F., J. MERCADER, J. RIBOT, A. PALOU, and M.L. BONET. 2005. Effects of retinoic acid administration and dietary vitamin A supplementation on leptin expression in mice: lack of correlation with changes of adipose tissue mass and food intake. Biochim Biophys Acta 1740:258-265.
471. ORBETTA, S., R. ANGIONI, A. CATTANEO, P. BECK-PECCOZ, and A. SPADA. 2006. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 154:83-86.
472. HELIOVAARA, M.K., A. REMITZ, S. REITAMO, A.M. TEPPO, S.L. KARONEN, and P. EBELING. 2007. 13-cis- Retinoic acid therapy induces insulin resistance, regulates inflammatory parameters, and paradoxically increases serum adiponectin concentration. Metabolism 56:786-791.
473. KOISTINEN, H.A., A. REMITZ, V.A. KOIVISTO, and P. EBELING. 2006. Paradoxical rise in serum adiponectin concentration in the face of acid-induced insulin resistance 13-cis-retinoic. Diabetologia 49:383-386.
474. KRSKOVA-TYBITANCLOVA, K., D. MACEJOVA, J. BRTKO, M. BACULIKOVA, O. KRIZANOVA, and S. ZORAD. 2008. Short term 13-cis-retinoic acid treatment at therapeutic doses elevates expression of leptin, GLUT4, PPARgamma and aP2 in rat adipose tissue. J Physiol Pharmacol 59:731-743.
475. STEINBERG, G.R., M.J.WATT, B.C. FAM, J. PROIETTO, S. ANDRIKOPOULOS, A.M. ALLEN, M.A. FEBBRAIO, and B.E. KEMP. 2006. Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. Endocrinology 147:3906-3914.
476. MATTHEWS, V.B., and M.A. FEBBRAIO. 2008. CNTF: a target therapeutic for obesity-related metabolic disease? J Mol Med 86:353-361.
477. WATT, M.J., N. DZAMKO, W.G. THOMAS, S. ROSE-JOHN, M. ERNST, D. CARLING, B.E. KEMP, M.A. FEBBRAIO, and G.R. STEINBERG. 2006. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12:541-548.
478. BLUHER, S., S. MOSCHOS, J. BULLEN, JR., E. KOKKOTOU, E. MARATOS-FLIER, S.J. WIEGAND, M.W. SLEEMAN, AND C.S.MANTZOROS. 2004. CILIARY NEUROTROPHIC FACTORAX15 ALTERS ENERGY HOMEOSTASIS, DECREASES BODY WEIGHT, AND IMPROVES METABOLIC CONTROL IN DIET-INDUCED OBESE AND UCP1-DTA MICE. DIABETES 53:2787-2796.
479. CEDARBAUM, J.M. for the ALS CNTF Treatment Study Group. 1996. A double-blind placebocontrolled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 46:1244-1249.
480. BLUHER, S., J. BULLEN, and C.S. MANTZOROS. 2008. Altered levels of adiponectin and adiponectin receptors may underlie the effect of ciliary neurotrophic factor (CNTF) to enhance insulin sensitivity in diet-induced obese mice. Horm Metab Res 40:225-227.
481. CROWE, S., S.M. TURPIN, F.KE, B.E. KEMP, and M.J.WATT. 2008. Metabolic remodeling in adipocytes promotes ciliary neurotrophic factor-mediated fat loss in obesity. Endocrinology 149:2546-2556.